aspirin has been researched along with Adenoma in 170 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Adenoma: A benign epithelial tumor with a glandular organization.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This paper introduces a recent paper on colorectal cancer prevention studies using aspirin." | 9.41 | [Aspirin for Chemoprevention of Colorectal Adenoma and Cancer]. ( Ishikawa, H, 2021) |
| "Although substantial evidence supports aspirin's efficacy in colorectal cancer chemoprevention, key molecular mechanisms are uncertain." | 9.34 | Metabolomics Analysis of Aspirin's Effects in Human Colon Tissue and Associations with Adenoma Risk. ( Baron, JA; Barry, EL; Fedirko, V; Jones, DP; Liu, K; Ma, C; Mott, LA; Passarelli, MN; Peacock, JL; Uppal, K, 2020) |
| " Several epidemiological studies have shown that regular use of low dose aspirin is associated with a 20 to 30% reduction in the risk of sporadic colonic adenomas and colorectal cancer regardless of family risk." | 9.34 | Effect of chemoprevention by low-dose aspirin of new or recurrent colorectal adenomas in patients with Lynch syndrome (AAS-Lynch): study protocol for a multicenter, double-blind, placebo-controlled randomized controlled trial. ( Ait-Omar, A; Benallaoua, M; Benamouzig, R; Boubaya, M; Deutsch, D; Helfen, S; Levy, V; Mary, F; Soualy, A, 2020) |
| "Among adults aged 40 to 80 years not using aspirin or other antithrombotic medications, administration of a single dose of oral aspirin prior to fecal immunochemical testing, compared with placebo, did not significantly increase test sensitivity for detecting advanced colorectal neoplasms at 2 predefined cutoffs of a quantitative fecal immunochemical test." | 9.30 | Effect of a Single Aspirin Dose Prior to Fecal Immunochemical Testing on Test Sensitivity for Detecting Advanced Colorectal Neoplasms: A Randomized Clinical Trial. ( Block, T; Böck, W; Brenner, H; Calderazzo, S; Czock, D; Dikopoulos, N; Eisenbach, T; Kopp-Schneider, A; Ludwig, L; Mangold, J; Seufferlein, T; Stolz, T; Tikk, K, 2019) |
| "Aspirin dosing strategies accounting for body weight suggested in previous trials of colorectal cancer may not apply to adenomas." | 9.30 | Body Composition and Aspirin Dose for Colorectal Adenoma Prevention in a Randomized Clinical Trial. ( Ahnen, DJ; Baron, JA; Barry, EL; Mott, LA; Passarelli, MN; Rees, JR, 2019) |
| "BCC incidence was evaluated in a randomized, double-blind, placebo-controlled clinical trial of aspirin (81 mg daily or 325 mg daily for ~3 years) and/or folic acid (1 mg daily for ~6 years) for the prevention of colorectal adenomas among 1121 participants with a previous adenoma." | 9.27 | Risk of basal cell carcinoma in a randomized clinical trial of aspirin and folic acid for the prevention of colorectal adenomas. ( Baron, JA; Barry, EL; Bresalier, RS; Gangar, P; Karagas, MR; McKeown-Eyssen, G; Passarelli, MN; Rees, JR; Zhang, D, 2018) |
| "The omega-3 polyunsaturated fatty acid eicosapentaenoic acid (EPA) and aspirin both have proof of concept for colorectal cancer chemoprevention, aligned with an excellent safety profile." | 9.27 | Eicosapentaenoic acid and aspirin, alone and in combination, for the prevention of colorectal adenomas (seAFOod Polyp Prevention trial): a multicentre, randomised, double-blind, placebo-controlled, 2 × 2 factorial trial. ( Clifford, G; Hepburn, T; Hull, MA; Loadman, PM; Logan, RF; Montgomery, AA; Rees, CJ; Shafayat, A; Sprange, K; Tan, W; Whitham, D; Williams, EA, 2018) |
| "Although aspirin is recommended for the prevention of colorectal cancer, the specific individuals for whom the benefits outweigh the risks are not clearly defined." | 9.24 | ASPirin Intervention for the REDuction of colorectal cancer risk (ASPIRED): a study protocol for a randomized controlled trial. ( Backman, V; Carolan, PJ; Chan, AT; Chin, SM; Chung, DC; Colizzo, FP; Drew, DA; Flagg, M; Freedman, M; Gala, M; Garber, JJ; Gilpin, KK; Huttenhower, C; Kedrin, D; Khalili, H; Kwon, DS; Markowitz, SD; Milne, GL; Nishioka, NS; Parziale, M; Pond, E; Rawlings, CA; Richter, JM; Roy, HK; Schuck, MM; Staller, K; Stewart, K; Wang, M, 2017) |
| " Most studies have demonstrated that the NSAID, aspirin, plays a beneficial role in the prevention of CRC and colonic adenomas." | 9.22 | Non-aspirin non-steroidal anti-inflammatory drugs in colorectal cancer: a review of clinical studies. ( Haydon, A; Orchard, SG; Zalcberg, JR; Zaman, FY, 2022) |
| "Aspirin (acetylsalicylic acid, ASA) is inexpensive and is established in preventing cardiovascular disease (CVD) and colorectal adenomas." | 9.22 | Aspirin and omega-3 polyunsaturated fatty acid use and their interaction in cardiovascular diseases and colorectal adenomas. ( Block, RC; Mousa, SA; Wang, IE; Yi, S, 2022) |
| "In a prospective study, the combination of calcitriol, aspirin, and calcium carbonate did not prevent recurrence of colorectal adenomas over a 3-year period." | 9.22 | Aspirin, Calcitriol, and Calcium Do Not Prevent Adenoma Recurrence in a Randomized Controlled Trial. ( Burcharth, J; Pommergaard, HC; Raskov, H; Rosenberg, J, 2016) |
| "Aspirin has been shown to protect against colorectal neoplasms; however, the optimal chemopreventive dose and underlying mechanisms are unclear." | 9.20 | Urinary metabolites of prostanoids and risk of recurrent colorectal adenomas in the Aspirin/Folate Polyp Prevention Study (AFPPS). ( Ahnen, DJ; Baron, JA; Barry, EL; Bradshaw, PT; Bresalier, RS; Fedirko, V; Figueiredo, JC; Milne, GL; Sandler, RS, 2015) |
| " The safety profile and potential cardiovascular benefits associated with ω-3 PUFAs make EPA a strong candidate for colorectal cancer (CRC) chemoprevention, alone or in combination with aspirin, which itself has recognized anti-CRC activity." | 9.17 | A randomized controlled trial of eicosapentaenoic acid and/or aspirin for colorectal adenoma prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme (The seAFOod Polyp Prevention Trial): study protocol for a randomized cont ( Clifford, GM; Hull, MA; Loadman, PM; Logan, RF; Montgomery, AA; Rees, CJ; Sandell, AC; Whitham, D, 2013) |
| "We investigated whether CYP2C9 genotype was associated with risk of colorectal adenoma and/or modified associations with aspirin treatment or cigarette smoking in a cohort of 928 participants in a randomized trial of aspirin chemoprevention." | 9.17 | CYP2C9 variants increase risk of colorectal adenoma recurrence and modify associations with smoking but not aspirin treatment. ( Ahnen, DJ; Baron, JA; Barry, EL; Bresalier, RS; Makar, KW; McKeown-Eyssen, GE; Mott, LA; Poole, EM; Sandler, RS; Ulrich, CM, 2013) |
| "272 patients (naive for chronic aspirin use) with colorectal adenomas were randomly assigned to treatment with lysine acetylsalicylate 160 mg/day (n=73) or 300 mg/day (n=67) or placebo (n=132) for 4 years." | 9.16 | Prevention by daily soluble aspirin of colorectal adenoma recurrence: 4-year results of the APACC randomised trial. ( Benamouzig, R; Chaussade, S; Deyra, J; Girard, B; Little, J; Martin, A; Uzzan, B, 2012) |
| " The protective effect of 81 mg of aspirin for colorectal adenomas persisted with continued posttreatment NSAID use." | 9.14 | Nonsteroidal anti-inflammatory drug use after 3 years of aspirin use and colorectal adenoma risk: observational follow-up of a randomized study. ( Ahnen, DJ; Baron, JA; Barry, EL; Bresalier, RS; Grau, MV; Gui, J; Haile, RW; McKeown-Eyssen, G; Sandler, RS; Summers, RW, 2009) |
| " Aspirin inhibits COX-2 activity and lowers the risk for colorectal adenomas and cancer." | 9.14 | Cyclooxygenase-2 polymorphisms, aspirin treatment, and risk for colorectal adenoma recurrence--data from a randomized clinical trial. ( Ahnen, DJ; Ali, IU; Baron, JA; Barry, EL; Bresalier, RS; Burke, C; Grau, MV; Gui, J; McKeown-Eyssen, GE; Munroe, DJ; Saibil, F; Sandler, RS; Sansbury, LB; Tsang, S, 2009) |
| "Low-dose aspirin reduces the incidence of colorectal cancer and recurrence of adenomas." | 9.14 | Cyclooxygenase-2 expression and recurrence of colorectal adenomas: effect of aspirin chemoprevention. ( Benamouzig, R; Chaussade, S; Deyra, J; Girard, B; Little, J; Martin, A; Uzzan, B, 2010) |
| "Study subjects, about half of whom were recruited after fortification of grain products with folic acid in the United States and Canada, consisted of 871 individuals with a recent history of one or more colorectal adenomas who were randomized to receive either a 1 mg/day folic acid supplement or a placebo within one of three randomly assigned aspirin treatment groups (placebo, 81, or 325 mg/day)." | 9.14 | Baseline plasma total homocysteine and adenoma recurrence: results from a double blind randomized clinical trial of aspirin and folate supplementation. ( Baron, JA; Grau, MV; Levine, AJ; Mott, LA; Ueland, PM, 2010) |
| "The Aspirin/Folate Polyp Prevention Study is a randomized clinical trial of folic acid supplementation and incidence of new colorectal adenomas in individuals with a history of adenomas (n = 1,084)." | 9.13 | Vitamins B2, B6, and B12 and risk of new colorectal adenomas in a randomized trial of aspirin use and folic acid supplementation. ( Ahnen, DJ; Ali, I; Baron, JA; Barry, EL; Figueiredo, JC; Grau, MV; Haile, RW; Levine, AJ; Midttun, O; Munroe, D; Sandler, RS; Tsang, S; Ueland, PM, 2008) |
| "8%) of 434 patients receiving aspirin had a recurrent adenoma compared with 121 (28." | 9.13 | Aspirin and folic acid for the prevention of recurrent colorectal adenomas. ( Armitage, NC; Grainge, MJ; Logan, RF; Muir, KR; Shepherd, VC, 2008) |
| " Overall, the results indicated that aspirin significantly reduced the risk of developing colorectal adenomas but not advanced lesions at 3 years (risk ratio (RR) = 0." | 9.12 | Influence of aspirin on prevention of colorectal cancer: an updated systematic review and meta-analysis of randomized controlled trials. ( Abdulhamid, AS; Alharbi, FA; Alomari, MS; Aziz, M; Ghaddaf, AA; Mullah, AN; Zaidi, SF, 2021) |
| "We randomly assigned patients who had adenomas removed before study entry to receive placebo (679 patients) or 200 mg (685 patients) or 400 mg (671 patients) of celecoxib twice daily." | 9.12 | Celecoxib for the prevention of sporadic colorectal adenomas. ( Anderson, WF; Bagheri, D; Bertagnolli, MM; Boisserie, F; Burn, J; Chung, DC; Corle, D; Dewar, T; Eagle, CJ; Foley, TR; Gordon, GB; Hawk, ET; Hess, TM; Hoffman, N; Kim, K; Macrae, F; Pruitt, RE; Redston, M; Rosenstein, RB; Saltzman, JR; Salzberg, B; Solomon, SD; Sylwestrowicz, T; Tang, J; Viner, JL; Wittes, J; Woloj, GM; Zauber, AG, 2006) |
| "The Prevention of Colorectal Sporadic Adenomatous Polyps trial was a randomized, placebo-controlled, double-blind study of the COX-2 inhibitor celecoxib given daily in a single 400-mg dose." | 9.12 | Celecoxib for the prevention of colorectal adenomatous polyps. ( Arber, N; Bhadra, P; Dite, P; Eagle, CJ; Fowler, R; Gerletti, P; Hajer, J; Lechuga, MJ; Levin, B; Macdonald, K; Rácz, I; Rosenstein, RB; Solomon, SD; Spicak, J; Tang, J; Wittes, J; Zauber, AG; Zavoral, M, 2006) |
| "To assess the safety and efficacy of folic acid supplementation for preventing colorectal adenomas." | 9.12 | Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. ( Ahnen, DJ; Allen, JI; Baron, JA; Barry, EL; Beck, GJ; Bond, JH; Bresalier, RS; Burke, CA; Byers, T; Church, TR; Cole, BF; Greenberg, ER; Haile, RW; Mandel, JS; Marcon, N; McKeown-Eyssen, G; Mott, LA; Pearson, LH; Rees, JR; Robertson, DJ; Rothstein, RI; Saibil, F; Sandler, RS; Snover, DC; Summers, RW; Ueland, PM, 2007) |
| "Regular use of aspirin and other nonsteroidal antiinflammatory drugs reduces both the development of colorectal neoplasia and recurrence of colorectal adenoma (CRA)." | 9.12 | Polymorphisms in PTGS1, PTGS2 and IL-10 do not influence colorectal adenoma recurrence in the context of a randomized aspirin intervention trial. ( Grainge, MJ; Houlston, RS; Hubner, RA; Liu, JF; Logan, RFA; Muir, KR, 2007) |
| "Experimental studies in animals and observational studies in humans suggest that regular aspirin use may decrease the risk of colorectal adenomas, the precursors to most colorectal cancers." | 9.10 | A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. ( Baron, JA; Budinger, S; Halabi, S; Karp, DD; Keresztes, R; Loprinzi, CL; Paskett, E; Petrelli, N; Pipas, JM; Sandler, RS; Schilsky, R; Steinbach, G, 2003) |
| "We performed a randomized, double-blind trial of aspirin as a chemopreventive agent against colorectal adenomas." | 9.10 | A randomized trial of aspirin to prevent colorectal adenomas. ( Ahnen, D; Allen, JI; Baron, JA; Beach, M; Beck, GJ; Bond, JH; Bresalier, R; Burke, CA; Byers, T; Church, TR; Cole, BF; Greenberg, ER; Haile, RW; Mandel, JS; Marcon, N; McKeown-Eyssen, G; Mott, LA; Pearson, L; Rothstein, R; Saibil, F; Sandler, RS; Snover, DC; Summers, RW; van Stolk, RU, 2003) |
| "Among the 238 patients who completed the year 1 colonoscopy, at least one adenoma was observed in 38 patients of the 126 (30%) in the aspirin group and in 46 of the 112 (41%) in the placebo group; relative risk was 0." | 9.10 | Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. ( Benamouzig, R; Chaussade, S; Coste, T; Couturier, D; Deyra, J; Girard, B; Jullian, E; Little, J; Martin, A; Piednoir, B, 2003) |
| " A multicentre, double-blind, randomized, controlled trial is underway to determine the efficacy of regular aspirin intake (160 or 300 mg/day) in reducing colorectal adenoma recurrence." | 9.09 | APACC, a French prospective study on aspirin efficacy in reducing colorectal adenoma recurrence: design and baseline findings. ( Benamouzig, R; Chaussade, S; Coste, T; Couturier, D; Deyra, J; Little, J; Martin, A; Yoon, H, 2001) |
| "To examine the relation between the use of aspirin and non-steroidal anti-inflammatory drugs and the presence of asymptomatic colorectal adenomas." | 9.07 | Effect of aspirin and non-steroidal anti-inflammatory drugs on colorectal adenomas: case-control study of subjects participating in the Nottingham faecal occult blood screening programme. ( Hardcastle, JD; Hawtin, PG; Little, J; Logan, RF, 1993) |
| "In patients with a previous history of colorectal cancer or adenomas, low-dose aspirin (80-160 mg/day) compared to placebo taken for 2 to 4 years reduces the risk of recurrent colorectal adenomas (relative risk (RR), 0." | 8.95 | Effects of aspirin and non-aspirin nonsteroidal anti-inflammatory drugs on the incidence of recurrent colorectal adenomas: a systematic review with meta-analysis and trial sequential analysis of randomized clinical trials. ( Chaiyakunapruk, N; Ching, SM; Lim, KG; Phisalprapa, P; Saokaew, S; Veettil, SK, 2017) |
| "Through search the possible randomized control trials, we make a renewed meta-analysis in order to assess the impact of aspirin in preventing the recurrence of colorectal adenoma." | 8.93 | The Efficacy of Aspirin in Preventing the Recurrence of Colorectal Adenoma: a Renewed Meta-Analysis of Randomized Trials. ( Cheng, DW; Gao, XK; Lu, XJ; Luo, H; Tu, J; Wang, Y; Wang, YJ; Xu, XL; Yan, BC; Zhang, HL; Zhao, TY, 2016) |
| "This meta-analysis suggests that aspirin prevents recurrent colorectal adenomas among patients with a history of colorectal adenomas." | 8.85 | The effect of aspirin in the recurrence of colorectal adenomas: a meta-analysis of randomized controlled trials. ( Cao, Y; Gao, F; Liao, C; Liu, L; Mo, Z; Tan, A, 2009) |
| "We combined data from all randomized double-blind placebo-controlled trials that evaluated aspirin for the prevention of colorectal adenomas." | 8.85 | Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. ( Baron, JA; Benamouzig, R; Chaussade, S; Cole, BF; Grainge, MJ; Halabi, S; Logan, RF; Sandler, RS, 2009) |
| "Aspirin for prevention of colorectal cancer is controversial." | 8.84 | The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. ( Barrowman, N; Code, C; Dubé, C; Lewin, G; Moher, D; Rostom, A; Sampson, M; Tsertsvadze, A, 2007) |
| "Randomised trials have shown that aspirin reduces the short-term risk of recurrent colorectal adenomas in patients with a history of adenomas or cancer, but large trials have shown no effect in primary prevention of colorectal cancer during 10 years' follow-up." | 8.84 | Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. ( Flossmann, E; Rothwell, PM, 2007) |
| "To evaluate the cost-effectiveness of aspirin chemoprevention alone and in combination with colonoscopy surveillance in patients with prior adenoma resection." | 8.84 | Aspirin chemoprevention in patients with increased risk for colorectal cancer: a cost-effectiveness analysis. ( Arguedas, MR; DuPont, AW; Wilcox, CM, 2007) |
| "There is combined evidence from three randomized trials that aspirin significantly reduced the recurrence of sporadic adenomatous polyps." | 8.82 | Nonsteroidal anti-inflammatory drugs and aspirin for the prevention of colorectal adenomas and cancer: a systematic review. ( Asano, TK; McLeod, RS, 2004) |
| "There is substantial experimental, clinical and epidemiological evidence that regular use of non-steroid anti-inflammatory drugs (NSAIDs), particularly aspirin, is associated with a reduced risk of colorectal cancer." | 8.79 | Aspirin, non-steroidal anti-inflammatory drugs and protection from colorectal cancer: a review of the epidemiological evidence. ( Forman, D; Weiss, HA, 1996) |
| "To analyze the risk of postoperative bleeding following endoscopic endonasal transsphenoidal surgery (EETS) for treatment of pituitary adenomas (PA) in patients with short-term discontinuation of low-dose aspirin, if required for prevention of artherothrombotic disease (ATD)." | 8.31 | Management and risk of postoperative bleeding in patients with low-dose antiplatelet aspirin medication during endoscopic endonasal surgery for pituitary adenomas. ( Alhallak, M; Enciu, A; Gerlach, R; Kellner, G; Lauten, A; Loeschner, D; Meyer, A; Steinbrecher, A, 2023) |
| "Aspirin intake has been shown to lead to significant protection against colorectal cancer, for example with an up to twofold reduction in colorectal adenoma incidence rates at higher doses." | 8.12 | Aspirin's effect on kinetic parameters of cells contributes to its role in reducing incidence of advanced colorectal adenomas, shown by a multiscale computational study. ( Boland, CR; Goel, A; Komarova, NL; Wang, Y; Wodarz, D, 2022) |
| "Aspirin has been shown to prevent the onset of colorectal adenoma and cancer." | 8.12 | Aspirin-Mediated Prevention of Colorectal Adenomas Recurrence is Affected by Blood Biochemistry and Nutritional Intake. ( Goto, C; Ishikawa, H; Itoh, Y; Matsuda, T; Mutoh, M; Otani, T; Sano, Y; Suzuki, S; Takeuchi, Y; Yoshida, N, 2022) |
| "Aspirin is a chemopreventive agent for colorectal adenoma and cancer (CRC) that, like many drugs inclusive of chemotherapeutics, has been investigated for its effects on bacterial growth and virulence gene expression." | 8.02 | Aspirin Modulation of the Colorectal Cancer-Associated Microbe Fusobacterium nucleatum. ( Brennan, CA; Chan, AT; Drew, DA; Gallini Comeau, CA; Garrett, WS; Glickman, JN; Nakatsu, G; Schoen, RE, 2021) |
| "With 13 years of follow-up, the authors prospectively evaluated the association between aspirin and ibuprofen use and incident distal adenoma (1221 cases), recurrent adenoma (862 cases), and incident colorectal cancer (CRC; 2826 cases) among men and women in the population-based Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial." | 8.02 | Aspirin, ibuprofen, and reduced risk of advanced colorectal adenoma incidence and recurrence and colorectal cancer in the PLCO Cancer Screening Trial. ( Barry, KH; Berndt, SI; Chudy-Onwugaje, K; Huang, WY; Johnson, CC; Katki, HA; Purdue, MP; Su, LJ; Wang, L, 2021) |
| "In a large screening cohort in Norway, regular use of aspirin and particularly DOACs, were associated with lower PPV of FIT for detection of CRCs and advanced adenomas." | 7.91 | Effects of Oral Anticoagulants and Aspirin on Performance of Fecal Immunochemical Tests in Colorectal Cancer Screening. ( Botteri, E; Bretthauer, M; de Lange, T; Frigstad, SO; Hoff, G; Holme, Ø; Randel, KR; Romstad, KMK, 2019) |
| "Clinical and cohort studies have shown that low-dose aspirin and calcium are effective low-risk strategies for primary prevention of colorectal cancer (CRC)." | 7.79 | Combination aspirin and/or calcium chemoprevention with colonoscopy in colorectal cancer prevention: cost-effectiveness analyses. ( Belasco, EJ; Lyford, CP; Pence, BC, 2013) |
| " In this study, we investigated the effects of long-term use (up to 25 years) of NSAIDs (ibuprofen or aspirin) on adenoma pathology and β-catenin-mediated signaling in sporadic human colon adenomas." | 7.77 | Ibuprofen inhibits activation of nuclear {beta}-catenin in human colon adenomas and induces the phosphorylation of GSK-3{beta}. ( Boardman, LA; Greenspan, EJ; Madigan, JP; Rosenberg, DW, 2011) |
| "The Aspirin/Folate Polyp Prevention Trial found that aspirin, but not folic acid, reduced recurrence of colorectal adenomas." | 7.75 | Antagonistic effects of aspirin and folic acid on inflammation markers and subsequent risk of recurrent colorectal adenomas. ( Ahnen, DJ; Baron, JA; Barry, EL; Bresalier, RS; Cushman, M; Ho, GY; McKeown-Eyssen, G; Rohan, TE; Saibil, F; Sandler, RS; Xue, X, 2009) |
| " Preventive Services Task Force (USPSTF) recommendation and supporting scientific evidence on routine use of aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer." | 7.74 | Routine aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer: U.S. Preventive Services Task Force recommendation statement. ( , 2007) |
| "We genotyped ODC G316A in 546 individuals in the United Kingdom Colorectal Adenoma Prevention trial of aspirin for CRA recurrence prevention and pooled our findings with data from two other randomized intervention trials." | 7.74 | Ornithine decarboxylase G316A genotype is prognostic for colorectal adenoma recurrence and predicts efficacy of aspirin chemoprevention. ( Grainge, MJ; Houlston, RS; Hubner, RA; Liu, JF; Logan, RF; Muir, KR, 2008) |
| "We tested these hypotheses among participants in the Aspirin/Folate Polyp Prevention Study who were randomly assigned to placebo or to aspirin treatment (81 or 325 mg daily) and followed for 3 years for the occurrence of new adenomas." | 7.73 | Ornithine decarboxylase polymorphism modification of response to aspirin treatment for colorectal adenoma prevention. ( Ahnen, DJ; Baron, JA; Barry, EL; Bhat, S; Burke, CA; Grau, MV; Haile, RW; O'Brien, TG; Sandler, RS, 2006) |
| "Randomized, double-blind, placebo-controlled trials have established that regular aspirin use reduces the risk for recurrent colorectal adenoma." | 7.72 | A prospective study of aspirin use and the risk for colorectal adenoma. ( Chan, AT; Colditz, GA; Fuchs, CS; Giovannucci, EL; Hunter, DJ; Schernhammer, ES; Willett, WC, 2004) |
| "Use of nonsteroidal antiinflammatory drugs (NSAIDs) has been associated with a reduced risk of colorectal cancer, but limited information is available on the effect of individual nonaspirin NSAIDs." | 7.71 | Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. ( García-Rodríguez, LA; Huerta-Alvarez, C, 2001) |
| "Aspirin and nonsteroidal anti-inflammatory drugs have been reported to protect against the development of colorectal cancer." | 7.70 | Aspirin and nonsteroidal anti-inflammatory agents and risk for colorectal adenomas. ( Galanko, JC; Helm, JF; Murray, SC; Sandler, RS; Woosley, JT, 1998) |
| "To determine whether regular use of aspirin decreases the risk for colorectal cancer." | 7.69 | Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. ( Ascherio, A; Colditz, GA; Giovannucci, E; Rimm, EB; Stampfer, MJ; Willett, WC, 1994) |
| "Regular aspirin intake may reduce the risk of colorectal cancer by 50%." | 7.69 | Differential growth inhibition by the aspirin metabolite salicylate in human colorectal tumor cell lines: enhanced apoptosis in carcinoma and in vitro-transformed adenoma relative to adenoma relative to adenoma cell lines. ( Elder, DJ; Hague, A; Hicks, DJ; Paraskeva, C, 1996) |
| "Patients who reported taking aspirin on both questionnaires (consistent users) had a lower risk of new adenomas at their 1-year follow-up colonoscopy (odds ratio = 0." | 7.68 | Reduced risk of large-bowel adenomas among aspirin users. The Polyp Prevention Study Group. ( Baron, JA; Freeman, DH; Greenberg, ER; Haile, R; Mandel, JS, 1993) |
| "Aspirin also plays a role by its anti-inflammatory action and the stimulation of antitumor immunity." | 6.58 | [Aspirin and colorectal cancer]. ( Di Fiore, F; Grancher, A; Michel, P; Sefrioui, D, 2018) |
| "Aspirin has been extensively investigated in the context of the prevention of cardiovascular disease." | 6.52 | Can We Select Patients for Colorectal Cancer Prevention with Aspirin? ( Arber, N; Kraus, S; Sion, D, 2015) |
| "Chemoprevention of colorectal cancer involves the long-term use of pharmacologic agents that can prevent neoplasms from developing in the large bowel." | 6.43 | Low dose aspirin, COX-inhibition and chemoprevention of colorectal cancer. ( Benamouzig, R; Chaussade, S; Little, J; Uzzan, B, 2005) |
| "Nine trials with 150 familial adenomatous polyposis (FAP) and 24,143 population subjects met the inclusion criteria." | 6.42 | Non steroidal anti-inflammatory drugs (NSAID) and Aspirin for preventing colorectal adenomas and carcinomas. ( Asano, TK; McLeod, RS, 2004) |
| " Thus, we assessed the efficacy associated with different dosing regimens of aspirin and naproxen." | 5.51 | Intermittent Dosing Regimens of Aspirin and Naproxen Inhibit Azoxymethane-Induced Colon Adenoma Progression to Adenocarcinoma and Invasive Carcinoma. ( Biddick, L; Janakiram, NB; Li, Q; Lightfoot, S; Lubet, RA; Madka, V; Miller, MS; Mohammed, A; Rao, CV; Sei, S; Singh, A; Steele, VE; Suen, CS; Zhang, Y, 2019) |
| "This paper introduces a recent paper on colorectal cancer prevention studies using aspirin." | 5.41 | [Aspirin for Chemoprevention of Colorectal Adenoma and Cancer]. ( Ishikawa, H, 2021) |
| " We performed a systematic review and network meta-analysis to assess the comparative efficacy and safety of candidate agents (low-dose aspirin [Asp], high-dose Asp, cyclooxygenase-2 inhibitors [coxibs], calcium, vitamin D, folic acid, ursodeoxycholic acid [UDCA], estrogen, and progesterone, alone or in combination) for preventing colorectal adenoma and CRC." | 5.41 | Chemoprevention of colorectal cancer in general population and high-risk population: a systematic review and network meta-analysis. ( Cao, Y; He, X; Li, J; Ma, Y; Wang, J; You, W; Zhang, Y, 2023) |
| "Although substantial evidence supports aspirin's efficacy in colorectal cancer chemoprevention, key molecular mechanisms are uncertain." | 5.34 | Metabolomics Analysis of Aspirin's Effects in Human Colon Tissue and Associations with Adenoma Risk. ( Baron, JA; Barry, EL; Fedirko, V; Jones, DP; Liu, K; Ma, C; Mott, LA; Passarelli, MN; Peacock, JL; Uppal, K, 2020) |
| " Several epidemiological studies have shown that regular use of low dose aspirin is associated with a 20 to 30% reduction in the risk of sporadic colonic adenomas and colorectal cancer regardless of family risk." | 5.34 | Effect of chemoprevention by low-dose aspirin of new or recurrent colorectal adenomas in patients with Lynch syndrome (AAS-Lynch): study protocol for a multicenter, double-blind, placebo-controlled randomized controlled trial. ( Ait-Omar, A; Benallaoua, M; Benamouzig, R; Boubaya, M; Deutsch, D; Helfen, S; Levy, V; Mary, F; Soualy, A, 2020) |
| "Among adults aged 40 to 80 years not using aspirin or other antithrombotic medications, administration of a single dose of oral aspirin prior to fecal immunochemical testing, compared with placebo, did not significantly increase test sensitivity for detecting advanced colorectal neoplasms at 2 predefined cutoffs of a quantitative fecal immunochemical test." | 5.30 | Effect of a Single Aspirin Dose Prior to Fecal Immunochemical Testing on Test Sensitivity for Detecting Advanced Colorectal Neoplasms: A Randomized Clinical Trial. ( Block, T; Böck, W; Brenner, H; Calderazzo, S; Czock, D; Dikopoulos, N; Eisenbach, T; Kopp-Schneider, A; Ludwig, L; Mangold, J; Seufferlein, T; Stolz, T; Tikk, K, 2019) |
| "Aspirin dosing strategies accounting for body weight suggested in previous trials of colorectal cancer may not apply to adenomas." | 5.30 | Body Composition and Aspirin Dose for Colorectal Adenoma Prevention in a Randomized Clinical Trial. ( Ahnen, DJ; Baron, JA; Barry, EL; Mott, LA; Passarelli, MN; Rees, JR, 2019) |
| "BCC incidence was evaluated in a randomized, double-blind, placebo-controlled clinical trial of aspirin (81 mg daily or 325 mg daily for ~3 years) and/or folic acid (1 mg daily for ~6 years) for the prevention of colorectal adenomas among 1121 participants with a previous adenoma." | 5.27 | Risk of basal cell carcinoma in a randomized clinical trial of aspirin and folic acid for the prevention of colorectal adenomas. ( Baron, JA; Barry, EL; Bresalier, RS; Gangar, P; Karagas, MR; McKeown-Eyssen, G; Passarelli, MN; Rees, JR; Zhang, D, 2018) |
| "The omega-3 polyunsaturated fatty acid eicosapentaenoic acid (EPA) and aspirin both have proof of concept for colorectal cancer chemoprevention, aligned with an excellent safety profile." | 5.27 | Eicosapentaenoic acid and aspirin, alone and in combination, for the prevention of colorectal adenomas (seAFOod Polyp Prevention trial): a multicentre, randomised, double-blind, placebo-controlled, 2 × 2 factorial trial. ( Clifford, G; Hepburn, T; Hull, MA; Loadman, PM; Logan, RF; Montgomery, AA; Rees, CJ; Shafayat, A; Sprange, K; Tan, W; Whitham, D; Williams, EA, 2018) |
| "Treatment with indomethacin, another PES inhibitor, also did not reduce the pulmonary BP metabolite:DNA adduct levels." | 5.27 | Effect of aspirin and indomethacin on the formation of benzo(a)pyrene-induced pulmonary adenomas and DNA adducts in A/HeJ mice. ( Adriaenssens, PI; Anderson, MW; Boorman, GA; Eling, TE; Sivarajah, K, 1983) |
| "Although aspirin is recommended for the prevention of colorectal cancer, the specific individuals for whom the benefits outweigh the risks are not clearly defined." | 5.24 | ASPirin Intervention for the REDuction of colorectal cancer risk (ASPIRED): a study protocol for a randomized controlled trial. ( Backman, V; Carolan, PJ; Chan, AT; Chin, SM; Chung, DC; Colizzo, FP; Drew, DA; Flagg, M; Freedman, M; Gala, M; Garber, JJ; Gilpin, KK; Huttenhower, C; Kedrin, D; Khalili, H; Kwon, DS; Markowitz, SD; Milne, GL; Nishioka, NS; Parziale, M; Pond, E; Rawlings, CA; Richter, JM; Roy, HK; Schuck, MM; Staller, K; Stewart, K; Wang, M, 2017) |
| " Most studies have demonstrated that the NSAID, aspirin, plays a beneficial role in the prevention of CRC and colonic adenomas." | 5.22 | Non-aspirin non-steroidal anti-inflammatory drugs in colorectal cancer: a review of clinical studies. ( Haydon, A; Orchard, SG; Zalcberg, JR; Zaman, FY, 2022) |
| "Aspirin (acetylsalicylic acid, ASA) is inexpensive and is established in preventing cardiovascular disease (CVD) and colorectal adenomas." | 5.22 | Aspirin and omega-3 polyunsaturated fatty acid use and their interaction in cardiovascular diseases and colorectal adenomas. ( Block, RC; Mousa, SA; Wang, IE; Yi, S, 2022) |
| "In a prospective study, the combination of calcitriol, aspirin, and calcium carbonate did not prevent recurrence of colorectal adenomas over a 3-year period." | 5.22 | Aspirin, Calcitriol, and Calcium Do Not Prevent Adenoma Recurrence in a Randomized Controlled Trial. ( Burcharth, J; Pommergaard, HC; Raskov, H; Rosenberg, J, 2016) |
| "Aspirin has been shown to protect against colorectal neoplasms; however, the optimal chemopreventive dose and underlying mechanisms are unclear." | 5.20 | Urinary metabolites of prostanoids and risk of recurrent colorectal adenomas in the Aspirin/Folate Polyp Prevention Study (AFPPS). ( Ahnen, DJ; Baron, JA; Barry, EL; Bradshaw, PT; Bresalier, RS; Fedirko, V; Figueiredo, JC; Milne, GL; Sandler, RS, 2015) |
| "311 subjects with single/multiple colorectal adenomas and adenocarcinomas excised by endoscopy were enrolled in the study (152 patients in the aspirin group and 159 patients in the placebo group)." | 5.19 | The preventive effects of low-dose enteric-coated aspirin tablets on the development of colorectal tumours in Asian patients: a randomised trial. ( Abe, T; Gondo, N; Goto, C; Iimuro, M; Ishikawa, H; Joh, T; Kitamura, S; Kudo, SE; Kusunoki, M; Lee, K; Matsuda, T; Matsuura, N; Mizuno, M; Mutoh, M; Okamura, S; Saida, Y; Sakai, T; Sano, Y; Sato, Y; Sugimoto, K; Suzuki, S; Tajika, M; Takayama, T; Tanaka, S; Tokudome, S; Wakabayashi, K; Yukawa, T, 2014) |
| " The safety profile and potential cardiovascular benefits associated with ω-3 PUFAs make EPA a strong candidate for colorectal cancer (CRC) chemoprevention, alone or in combination with aspirin, which itself has recognized anti-CRC activity." | 5.17 | A randomized controlled trial of eicosapentaenoic acid and/or aspirin for colorectal adenoma prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme (The seAFOod Polyp Prevention Trial): study protocol for a randomized cont ( Clifford, GM; Hull, MA; Loadman, PM; Logan, RF; Montgomery, AA; Rees, CJ; Sandell, AC; Whitham, D, 2013) |
| "We investigated whether CYP2C9 genotype was associated with risk of colorectal adenoma and/or modified associations with aspirin treatment or cigarette smoking in a cohort of 928 participants in a randomized trial of aspirin chemoprevention." | 5.17 | CYP2C9 variants increase risk of colorectal adenoma recurrence and modify associations with smoking but not aspirin treatment. ( Ahnen, DJ; Baron, JA; Barry, EL; Bresalier, RS; Makar, KW; McKeown-Eyssen, GE; Mott, LA; Poole, EM; Sandler, RS; Ulrich, CM, 2013) |
| "272 patients (naive for chronic aspirin use) with colorectal adenomas were randomly assigned to treatment with lysine acetylsalicylate 160 mg/day (n=73) or 300 mg/day (n=67) or placebo (n=132) for 4 years." | 5.16 | Prevention by daily soluble aspirin of colorectal adenoma recurrence: 4-year results of the APACC randomised trial. ( Benamouzig, R; Chaussade, S; Deyra, J; Girard, B; Little, J; Martin, A; Uzzan, B, 2012) |
| " The protective effect of 81 mg of aspirin for colorectal adenomas persisted with continued posttreatment NSAID use." | 5.14 | Nonsteroidal anti-inflammatory drug use after 3 years of aspirin use and colorectal adenoma risk: observational follow-up of a randomized study. ( Ahnen, DJ; Baron, JA; Barry, EL; Bresalier, RS; Grau, MV; Gui, J; Haile, RW; McKeown-Eyssen, G; Sandler, RS; Summers, RW, 2009) |
| " We studied prostate cancer occurrence in the Aspirin/Folate Polyp Prevention Study, a placebo-controlled randomized trial of aspirin and folic acid supplementation for the chemoprevention of colorectal adenomas conducted between July 6, 1994, and December 31, 2006." | 5.14 | Folic acid and risk of prostate cancer: results from a randomized clinical trial. ( Baron, JA; Bresalier, RS; Burke, CA; Figueiredo, JC; Grau, MV; Haile, RW; McKeown-Eyssen, GE; Sandler, RS; Summers, RW, 2009) |
| "Our data were collected as part of a randomized clinical trial testing the efficacy of aspirin and folic acid for the prevention of colorectal adenomas." | 5.14 | Global DNA hypomethylation (LINE-1) in the normal colon and lifestyle characteristics and dietary and genetic factors. ( Baron, JA; Bresalier, RS; Chen, X; Figueiredo, JC; Grau, MV; Haile, RW; Hamdan, R; Issa, JP; Levine, AJ; McKeown-Eyssen, G; Shen, L; Wallace, K, 2009) |
| " Aspirin inhibits COX-2 activity and lowers the risk for colorectal adenomas and cancer." | 5.14 | Cyclooxygenase-2 polymorphisms, aspirin treatment, and risk for colorectal adenoma recurrence--data from a randomized clinical trial. ( Ahnen, DJ; Ali, IU; Baron, JA; Barry, EL; Bresalier, RS; Burke, C; Grau, MV; Gui, J; McKeown-Eyssen, GE; Munroe, DJ; Saibil, F; Sandler, RS; Sansbury, LB; Tsang, S, 2009) |
| "Low-dose aspirin reduces the incidence of colorectal cancer and recurrence of adenomas." | 5.14 | Cyclooxygenase-2 expression and recurrence of colorectal adenomas: effect of aspirin chemoprevention. ( Benamouzig, R; Chaussade, S; Deyra, J; Girard, B; Little, J; Martin, A; Uzzan, B, 2010) |
| "Study subjects, about half of whom were recruited after fortification of grain products with folic acid in the United States and Canada, consisted of 871 individuals with a recent history of one or more colorectal adenomas who were randomized to receive either a 1 mg/day folic acid supplement or a placebo within one of three randomly assigned aspirin treatment groups (placebo, 81, or 325 mg/day)." | 5.14 | Baseline plasma total homocysteine and adenoma recurrence: results from a double blind randomized clinical trial of aspirin and folate supplementation. ( Baron, JA; Grau, MV; Levine, AJ; Mott, LA; Ueland, PM, 2010) |
| "The Aspirin/Folate Polyp Prevention Study is a randomized clinical trial of folic acid supplementation and incidence of new colorectal adenomas in individuals with a history of adenomas (n = 1,084)." | 5.13 | Vitamins B2, B6, and B12 and risk of new colorectal adenomas in a randomized trial of aspirin use and folic acid supplementation. ( Ahnen, DJ; Ali, I; Baron, JA; Barry, EL; Figueiredo, JC; Grau, MV; Haile, RW; Levine, AJ; Midttun, O; Munroe, D; Sandler, RS; Tsang, S; Ueland, PM, 2008) |
| " We assessed the association between two common MTHFR variants, 677C>T and 1298A>C, and adenoma recurrence in the context of a randomized double- blind clinical trial of aspirin use and folate supplementation." | 5.13 | MTHFR genotype and colorectal adenoma recurrence: data from a double-blind placebo-controlled clinical trial. ( Ahnen, D; Ali, IU; Baron, JA; Barry, EL; Cole, BF; Haile, RW; Levine, AJ; Munroe, DJ; Saibil, F; Tsang, S; Ueland, P; Wallace, K, 2008) |
| "The Aspirin/Folate Polyp Prevention Study is a randomized, placebo-controlled trial of aspirin use and folic acid supplementation and incidence of colorectal adenomas in individuals with a history of these lesions." | 5.13 | Colorectal adenomas in a randomized folate trial: the role of baseline dietary and circulating folate levels. ( Ahnen, DJ; Baron, JA; Barry, EL; Bond, J; Bresalier, RS; Byers, T; Figueiredo, JC; Grau, MV; Haile, RW; Levine, AJ; McKeown-Eyssen, GE; Sandler, RS; Summers, RW; Ueland, PM, 2008) |
| "In a randomized, placebo-controlled trial, we used a two-by-two design to investigate the effects of aspirin, at a dose of 600 mg per day, and resistant starch (Novelose), at a dose of 30 g per day, in reducing the risk of adenoma and carcinoma among persons with the Lynch syndrome." | 5.13 | Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. ( Barker, G; Bertario, L; Bisgaard, ML; Bishop, DT; Burn, J; Dunlop, M; Eccles, D; Elliott, F; Evans, DG; Fodde, R; Ho, JW; Jarvinen, HJ; Jass, JR; Lindblom, A; Lubinski, J; Lynch, HT; Macrae, F; Maher, ER; Mathers, JC; Mecklin, JP; Morrison, PJ; Möslein, G; Olschwang, S; Ramesar, R; Scott, RJ; Side, L; Thomas, HJ; Vasen, HF, 2008) |
| "8%) of 434 patients receiving aspirin had a recurrent adenoma compared with 121 (28." | 5.13 | Aspirin and folic acid for the prevention of recurrent colorectal adenomas. ( Armitage, NC; Grainge, MJ; Logan, RF; Muir, KR; Shepherd, VC, 2008) |
| " Overall, the results indicated that aspirin significantly reduced the risk of developing colorectal adenomas but not advanced lesions at 3 years (risk ratio (RR) = 0." | 5.12 | Influence of aspirin on prevention of colorectal cancer: an updated systematic review and meta-analysis of randomized controlled trials. ( Abdulhamid, AS; Alharbi, FA; Alomari, MS; Aziz, M; Ghaddaf, AA; Mullah, AN; Zaidi, SF, 2021) |
| "We randomly assigned patients who had adenomas removed before study entry to receive placebo (679 patients) or 200 mg (685 patients) or 400 mg (671 patients) of celecoxib twice daily." | 5.12 | Celecoxib for the prevention of sporadic colorectal adenomas. ( Anderson, WF; Bagheri, D; Bertagnolli, MM; Boisserie, F; Burn, J; Chung, DC; Corle, D; Dewar, T; Eagle, CJ; Foley, TR; Gordon, GB; Hawk, ET; Hess, TM; Hoffman, N; Kim, K; Macrae, F; Pruitt, RE; Redston, M; Rosenstein, RB; Saltzman, JR; Salzberg, B; Solomon, SD; Sylwestrowicz, T; Tang, J; Viner, JL; Wittes, J; Woloj, GM; Zauber, AG, 2006) |
| "The Prevention of Colorectal Sporadic Adenomatous Polyps trial was a randomized, placebo-controlled, double-blind study of the COX-2 inhibitor celecoxib given daily in a single 400-mg dose." | 5.12 | Celecoxib for the prevention of colorectal adenomatous polyps. ( Arber, N; Bhadra, P; Dite, P; Eagle, CJ; Fowler, R; Gerletti, P; Hajer, J; Lechuga, MJ; Levin, B; Macdonald, K; Rácz, I; Rosenstein, RB; Solomon, SD; Spicak, J; Tang, J; Wittes, J; Zauber, AG; Zavoral, M, 2006) |
| " Functional polymorphisms of UGT1A6 (T181A and R184S) and CYP2C9 (R144C and I359L) have been reported to modify the protective effect of aspirin on colorectal adenoma risk." | 5.12 | Genetic variants of UGT1A6 influence risk of colorectal adenoma recurrence. ( Armitage, N; Grainge, M; Houlston, RS; Hubner, RA; Liu, JF; Logan, RF; Muir, KR; Popat, S; Shepherd, V, 2006) |
| "To assess the safety and efficacy of folic acid supplementation for preventing colorectal adenomas." | 5.12 | Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. ( Ahnen, DJ; Allen, JI; Baron, JA; Barry, EL; Beck, GJ; Bond, JH; Bresalier, RS; Burke, CA; Byers, T; Church, TR; Cole, BF; Greenberg, ER; Haile, RW; Mandel, JS; Marcon, N; McKeown-Eyssen, G; Mott, LA; Pearson, LH; Rees, JR; Robertson, DJ; Rothstein, RI; Saibil, F; Sandler, RS; Snover, DC; Summers, RW; Ueland, PM, 2007) |
| "Regular use of aspirin and other nonsteroidal antiinflammatory drugs reduces both the development of colorectal neoplasia and recurrence of colorectal adenoma (CRA)." | 5.12 | Polymorphisms in PTGS1, PTGS2 and IL-10 do not influence colorectal adenoma recurrence in the context of a randomized aspirin intervention trial. ( Grainge, MJ; Houlston, RS; Hubner, RA; Liu, JF; Logan, RFA; Muir, KR, 2007) |
| "Experimental studies in animals and observational studies in humans suggest that regular aspirin use may decrease the risk of colorectal adenomas, the precursors to most colorectal cancers." | 5.10 | A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. ( Baron, JA; Budinger, S; Halabi, S; Karp, DD; Keresztes, R; Loprinzi, CL; Paskett, E; Petrelli, N; Pipas, JM; Sandler, RS; Schilsky, R; Steinbach, G, 2003) |
| "We performed a randomized, double-blind trial of aspirin as a chemopreventive agent against colorectal adenomas." | 5.10 | A randomized trial of aspirin to prevent colorectal adenomas. ( Ahnen, D; Allen, JI; Baron, JA; Beach, M; Beck, GJ; Bond, JH; Bresalier, R; Burke, CA; Byers, T; Church, TR; Cole, BF; Greenberg, ER; Haile, RW; Mandel, JS; Marcon, N; McKeown-Eyssen, G; Mott, LA; Pearson, L; Rothstein, R; Saibil, F; Sandler, RS; Snover, DC; Summers, RW; van Stolk, RU, 2003) |
| "Among the 238 patients who completed the year 1 colonoscopy, at least one adenoma was observed in 38 patients of the 126 (30%) in the aspirin group and in 46 of the 112 (41%) in the placebo group; relative risk was 0." | 5.10 | Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. ( Benamouzig, R; Chaussade, S; Coste, T; Couturier, D; Deyra, J; Girard, B; Jullian, E; Little, J; Martin, A; Piednoir, B, 2003) |
| " A multicentre, double-blind, randomized, controlled trial is underway to determine the efficacy of regular aspirin intake (160 or 300 mg/day) in reducing colorectal adenoma recurrence." | 5.09 | APACC, a French prospective study on aspirin efficacy in reducing colorectal adenoma recurrence: design and baseline findings. ( Benamouzig, R; Chaussade, S; Coste, T; Couturier, D; Deyra, J; Little, J; Martin, A; Yoon, H, 2001) |
| "To examine the relation between the use of aspirin and non-steroidal anti-inflammatory drugs and the presence of asymptomatic colorectal adenomas." | 5.07 | Effect of aspirin and non-steroidal anti-inflammatory drugs on colorectal adenomas: case-control study of subjects participating in the Nottingham faecal occult blood screening programme. ( Hardcastle, JD; Hawtin, PG; Little, J; Logan, RF, 1993) |
| "In patients with a previous history of colorectal cancer or adenomas, low-dose aspirin (80-160 mg/day) compared to placebo taken for 2 to 4 years reduces the risk of recurrent colorectal adenomas (relative risk (RR), 0." | 4.95 | Effects of aspirin and non-aspirin nonsteroidal anti-inflammatory drugs on the incidence of recurrent colorectal adenomas: a systematic review with meta-analysis and trial sequential analysis of randomized clinical trials. ( Chaiyakunapruk, N; Ching, SM; Lim, KG; Phisalprapa, P; Saokaew, S; Veettil, SK, 2017) |
| "Through search the possible randomized control trials, we make a renewed meta-analysis in order to assess the impact of aspirin in preventing the recurrence of colorectal adenoma." | 4.93 | The Efficacy of Aspirin in Preventing the Recurrence of Colorectal Adenoma: a Renewed Meta-Analysis of Randomized Trials. ( Cheng, DW; Gao, XK; Lu, XJ; Luo, H; Tu, J; Wang, Y; Wang, YJ; Xu, XL; Yan, BC; Zhang, HL; Zhao, TY, 2016) |
| "This meta-analysis suggests that aspirin prevents recurrent colorectal adenomas among patients with a history of colorectal adenomas." | 4.85 | The effect of aspirin in the recurrence of colorectal adenomas: a meta-analysis of randomized controlled trials. ( Cao, Y; Gao, F; Liao, C; Liu, L; Mo, Z; Tan, A, 2009) |
| "We combined data from all randomized double-blind placebo-controlled trials that evaluated aspirin for the prevention of colorectal adenomas." | 4.85 | Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. ( Baron, JA; Benamouzig, R; Chaussade, S; Cole, BF; Grainge, MJ; Halabi, S; Logan, RF; Sandler, RS, 2009) |
| "Aspirin for prevention of colorectal cancer is controversial." | 4.84 | The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. ( Barrowman, N; Code, C; Dubé, C; Lewin, G; Moher, D; Rostom, A; Sampson, M; Tsertsvadze, A, 2007) |
| "Randomised trials have shown that aspirin reduces the short-term risk of recurrent colorectal adenomas in patients with a history of adenomas or cancer, but large trials have shown no effect in primary prevention of colorectal cancer during 10 years' follow-up." | 4.84 | Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. ( Flossmann, E; Rothwell, PM, 2007) |
| "To evaluate the cost-effectiveness of aspirin chemoprevention alone and in combination with colonoscopy surveillance in patients with prior adenoma resection." | 4.84 | Aspirin chemoprevention in patients with increased risk for colorectal cancer: a cost-effectiveness analysis. ( Arguedas, MR; DuPont, AW; Wilcox, CM, 2007) |
| "There is combined evidence from three randomized trials that aspirin significantly reduced the recurrence of sporadic adenomatous polyps." | 4.82 | Nonsteroidal anti-inflammatory drugs and aspirin for the prevention of colorectal adenomas and cancer: a systematic review. ( Asano, TK; McLeod, RS, 2004) |
| "There is substantial experimental, clinical and epidemiological evidence that regular use of non-steroid anti-inflammatory drugs (NSAIDs), particularly aspirin, is associated with a reduced risk of colorectal cancer." | 4.79 | Aspirin, non-steroidal anti-inflammatory drugs and protection from colorectal cancer: a review of the epidemiological evidence. ( Forman, D; Weiss, HA, 1996) |
| "In rodents, nonsteroidal anti-inflammatory drugs (NSAIDs) including aspirin inhibit chemically induced adenomas and early carcinomas of the colon." | 4.79 | Aspirin and gastrointestinal cancer. ( Thun, MJ, 1997) |
| "The possible protective effect of aspirin on risk of colorectal cancer (CRC) is still highly debated." | 4.31 | Association between use of low-dose aspirin and detection of colorectal polyps and cancer in a screening setting. ( Botteri, E; Hoff, G; Holme, Ø; Nafisi, S; Randel, KR; Schult, AL; Støer, NC; Veierød, MB, 2023) |
| "To analyze the risk of postoperative bleeding following endoscopic endonasal transsphenoidal surgery (EETS) for treatment of pituitary adenomas (PA) in patients with short-term discontinuation of low-dose aspirin, if required for prevention of artherothrombotic disease (ATD)." | 4.31 | Management and risk of postoperative bleeding in patients with low-dose antiplatelet aspirin medication during endoscopic endonasal surgery for pituitary adenomas. ( Alhallak, M; Enciu, A; Gerlach, R; Kellner, G; Lauten, A; Loeschner, D; Meyer, A; Steinbrecher, A, 2023) |
| "Aspirin intake has been shown to lead to significant protection against colorectal cancer, for example with an up to twofold reduction in colorectal adenoma incidence rates at higher doses." | 4.12 | Aspirin's effect on kinetic parameters of cells contributes to its role in reducing incidence of advanced colorectal adenomas, shown by a multiscale computational study. ( Boland, CR; Goel, A; Komarova, NL; Wang, Y; Wodarz, D, 2022) |
| "Aspirin has been shown to prevent the onset of colorectal adenoma and cancer." | 4.12 | Aspirin-Mediated Prevention of Colorectal Adenomas Recurrence is Affected by Blood Biochemistry and Nutritional Intake. ( Goto, C; Ishikawa, H; Itoh, Y; Matsuda, T; Mutoh, M; Otani, T; Sano, Y; Suzuki, S; Takeuchi, Y; Yoshida, N, 2022) |
| "Aspirin reduces the incidence of conventional adenomas driven by APC mutation and thus colorectal cancer." | 4.02 | Aspirin reduces the incidence of metastasis in a pre-clinical study of Braf mutant serrated colorectal neoplasia. ( Bond, CE; Fennell, LJ; Kane, AM; Leggett, BA; Liu, C; McKeone, DM; Pollock, PM; Whitehall, VLJ; Young, G, 2021) |
| "Aspirin is a chemopreventive agent for colorectal adenoma and cancer (CRC) that, like many drugs inclusive of chemotherapeutics, has been investigated for its effects on bacterial growth and virulence gene expression." | 4.02 | Aspirin Modulation of the Colorectal Cancer-Associated Microbe Fusobacterium nucleatum. ( Brennan, CA; Chan, AT; Drew, DA; Gallini Comeau, CA; Garrett, WS; Glickman, JN; Nakatsu, G; Schoen, RE, 2021) |
| "With 13 years of follow-up, the authors prospectively evaluated the association between aspirin and ibuprofen use and incident distal adenoma (1221 cases), recurrent adenoma (862 cases), and incident colorectal cancer (CRC; 2826 cases) among men and women in the population-based Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial." | 4.02 | Aspirin, ibuprofen, and reduced risk of advanced colorectal adenoma incidence and recurrence and colorectal cancer in the PLCO Cancer Screening Trial. ( Barry, KH; Berndt, SI; Chudy-Onwugaje, K; Huang, WY; Johnson, CC; Katki, HA; Purdue, MP; Su, LJ; Wang, L, 2021) |
| "In a large screening cohort in Norway, regular use of aspirin and particularly DOACs, were associated with lower PPV of FIT for detection of CRCs and advanced adenomas." | 3.91 | Effects of Oral Anticoagulants and Aspirin on Performance of Fecal Immunochemical Tests in Colorectal Cancer Screening. ( Botteri, E; Bretthauer, M; de Lange, T; Frigstad, SO; Hoff, G; Holme, Ø; Randel, KR; Romstad, KMK, 2019) |
| " As an illustration, we apply the methods to data from the Aspirin/Folate Polyp Prevention Study, a clinical trial evaluating the effect of oral aspirin, folic acid, or both as a chemoprevention agent against colorectal adenomas." | 3.83 | Subpopulation Treatment Effect Pattern Plot (STEPP) analysis for continuous, binary, and count outcomes. ( Barcella, W; Bonetti, M; Cole, BF; Gelber, RD; Lazar, A; Wang, XV; Yip, WK, 2016) |
| "Clinical and cohort studies have shown that low-dose aspirin and calcium are effective low-risk strategies for primary prevention of colorectal cancer (CRC)." | 3.79 | Combination aspirin and/or calcium chemoprevention with colonoscopy in colorectal cancer prevention: cost-effectiveness analyses. ( Belasco, EJ; Lyford, CP; Pence, BC, 2013) |
| " In this study, we investigated the effects of long-term use (up to 25 years) of NSAIDs (ibuprofen or aspirin) on adenoma pathology and β-catenin-mediated signaling in sporadic human colon adenomas." | 3.77 | Ibuprofen inhibits activation of nuclear {beta}-catenin in human colon adenomas and induces the phosphorylation of GSK-3{beta}. ( Boardman, LA; Greenspan, EJ; Madigan, JP; Rosenberg, DW, 2011) |
| "The Aspirin/Folate Polyp Prevention Trial found that aspirin, but not folic acid, reduced recurrence of colorectal adenomas." | 3.75 | Antagonistic effects of aspirin and folic acid on inflammation markers and subsequent risk of recurrent colorectal adenomas. ( Ahnen, DJ; Baron, JA; Barry, EL; Bresalier, RS; Cushman, M; Ho, GY; McKeown-Eyssen, G; Rohan, TE; Saibil, F; Sandler, RS; Xue, X, 2009) |
| " Preventive Services Task Force (USPSTF) recommendation and supporting scientific evidence on routine use of aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer." | 3.74 | Routine aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer: U.S. Preventive Services Task Force recommendation statement. ( , 2007) |
| "We genotyped ODC G316A in 546 individuals in the United Kingdom Colorectal Adenoma Prevention trial of aspirin for CRA recurrence prevention and pooled our findings with data from two other randomized intervention trials." | 3.74 | Ornithine decarboxylase G316A genotype is prognostic for colorectal adenoma recurrence and predicts efficacy of aspirin chemoprevention. ( Grainge, MJ; Houlston, RS; Hubner, RA; Liu, JF; Logan, RF; Muir, KR, 2008) |
| "To explore the separate and joint effects of calcium and aspirin/nonsteroidal anti-inflammatory drugs (NSAID), we used data from two large randomized clinical trials among patients with a recent history of colorectal adenomas." | 3.73 | Interaction of calcium supplementation and nonsteroidal anti-inflammatory drugs and the risk of colorectal adenomas. ( Baron, JA; Barry, EL; Cole, BF; Grau, MV; Haile, RW; Mandel, JS; Sandler, RS, 2005) |
| "We tested these hypotheses among participants in the Aspirin/Folate Polyp Prevention Study who were randomly assigned to placebo or to aspirin treatment (81 or 325 mg daily) and followed for 3 years for the occurrence of new adenomas." | 3.73 | Ornithine decarboxylase polymorphism modification of response to aspirin treatment for colorectal adenoma prevention. ( Ahnen, DJ; Baron, JA; Barry, EL; Bhat, S; Burke, CA; Grau, MV; Haile, RW; O'Brien, TG; Sandler, RS, 2006) |
| "The nonsteroidal anti-inflammatory drug aspirin and the spice curcumin retard adenoma formation when administered long-term to Apc(Min/+) mice, a model of human familial adenomatous polyposis coli." | 3.72 | Age-related difference in susceptibility of Apc(Min/+) mice towards the chemopreventive efficacy of dietary aspirin and curcumin. ( Clarke, AR; Gescher, A; Perkins, S; Steward, W, 2003) |
| "We investigated the primary adenoma cells and HT-29 cells in an attempt to know whether NaBT and two NSAIDs (aspirin and NS-398) could be used as effective adjuvant for reducing cell proliferation, and to explore the possible mechanisms therein involved." | 3.72 | [Effects of NaBT and NSAIDs on colorectal adenoma-carcinoma cells]. ( Gan, H; Ouyang, Q; Zhang, Z, 2003) |
| "Randomized, double-blind, placebo-controlled trials have established that regular aspirin use reduces the risk for recurrent colorectal adenoma." | 3.72 | A prospective study of aspirin use and the risk for colorectal adenoma. ( Chan, AT; Colditz, GA; Fuchs, CS; Giovannucci, EL; Hunter, DJ; Schernhammer, ES; Willett, WC, 2004) |
| "Regular aspirin use is associated with a reduced risk for colorectal adenoma, whereas smoking increases risk." | 3.72 | A prospective study of genetic polymorphisms in the cytochrome P-450 2C9 enzyme and the risk for distal colorectal adenoma. ( Chan, AT; Fuchs, CS; Giovannucci, EL; Hunter, DJ; Tranah, GJ, 2004) |
| "Use of nonsteroidal antiinflammatory drugs (NSAIDs) has been associated with a reduced risk of colorectal cancer, but limited information is available on the effect of individual nonaspirin NSAIDs." | 3.71 | Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. ( García-Rodríguez, LA; Huerta-Alvarez, C, 2001) |
| "Aspirin and nonsteroidal anti-inflammatory drugs have been reported to protect against the development of colorectal cancer." | 3.70 | Aspirin and nonsteroidal anti-inflammatory agents and risk for colorectal adenomas. ( Galanko, JC; Helm, JF; Murray, SC; Sandler, RS; Woosley, JT, 1998) |
| "The Apc1638N mouse model, which carries a targeted mutant allele within the adenomatous polyposis (Apc) gene and develops intestinal tumours spontaneously, predominantly in the small bowel, was used to investigate the effects of two potential chemopreventive agents, aspirin and alpha-amylase resistant starch (RS)." | 3.70 | Intestinal tumorigenesis in the Apc1638N mouse treated with aspirin and resistant starch for up to 5 months. ( Burn, J; Coaker, J; Fodde, R; Kartheuser, A; Kooshkghazi, MD; Mathers, JC; Williamson, SL, 1999) |
| "To determine whether regular use of aspirin decreases the risk for colorectal cancer." | 3.69 | Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. ( Ascherio, A; Colditz, GA; Giovannucci, E; Rimm, EB; Stampfer, MJ; Willett, WC, 1994) |
| "Regular aspirin intake may reduce the risk of colorectal cancer by 50%." | 3.69 | Differential growth inhibition by the aspirin metabolite salicylate in human colorectal tumor cell lines: enhanced apoptosis in carcinoma and in vitro-transformed adenoma relative to adenoma relative to adenoma cell lines. ( Elder, DJ; Hague, A; Hicks, DJ; Paraskeva, C, 1996) |
| "Our objective was to study the relationship between dispensed aspirin, nonaspirin nonsteroidal antiinflammatory drugs (NSAIDs), steroidal antiinflammatory drugs (SAIDs), acetaminophen, calcium, psyllium, and multivitamin preparations and the risk for subsequent colorectal adenoma and adenocarcinoma." | 3.69 | Long-term use of nonsteroidal antiinflammatory drugs and other chemopreventors and risk of subsequent colorectal neoplasia. ( Clark, WS; Cotsonis, GA; Lubin, MF; Peleg, II; Wilcox, CM, 1996) |
| "Patients who reported taking aspirin on both questionnaires (consistent users) had a lower risk of new adenomas at their 1-year follow-up colonoscopy (odds ratio = 0." | 3.68 | Reduced risk of large-bowel adenomas among aspirin users. The Polyp Prevention Study Group. ( Baron, JA; Freeman, DH; Greenberg, ER; Haile, R; Mandel, JS, 1993) |
| "Invasive colorectal cancer incidence." | 2.72 | Low-fat dietary pattern and risk of colorectal cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. ( Anderson, GL; Assaf, AR; Bassford, T; Beresford, SA; Black, HR; Bowen, D; Brunner, RL; Brzyski, RG; Caan, B; Chlebowski, RT; Gass, M; Harrigan, RC; Hays, J; Heber, D; Heiss, G; Hendrix, SL; Howard, BV; Hsia, J; Hubbell, FA; Jackson, RD; Johnson, KC; Kotchen, JM; Kuller, LH; LaCroix, AZ; Lane, DS; Langer, RD; Lasser, NL; Lewis, CE; Manson, JE; Margolis, KL; Mossavar-Rahmani, Y; Ockene, JK; Parker, LM; Perri, MG; Phillips, L; Prentice, RL; Ritenbaugh, C; Robbins, J; Rossouw, JE; Sarto, GE; Snetselaar, LG; Stefanick, ML; Van Horn, L; Vitolins, MZ; Wactawski-Wende, J; Wallace, RB; Whitlock, E, 2006) |
| "Odds ratios (ORs) for adenoma recurrence were calculated using the lowest quartile of fiber intake as the reference." | 2.70 | Baseline dietary fiber intake and colorectal adenoma recurrence in the wheat bran fiber randomized trial. ( Alberts, DS; Giuliano, AR; Guillén-Rodríguez, JM; Jacobs, ET; Martínez, ME; Roe, DJ, 2002) |
| "Aspirin also plays a role by its anti-inflammatory action and the stimulation of antitumor immunity." | 2.58 | [Aspirin and colorectal cancer]. ( Di Fiore, F; Grancher, A; Michel, P; Sefrioui, D, 2018) |
| "Lynch syndrome is an autosomal-dominant hereditary cancer syndrome." | 2.55 | Approach to Lynch Syndrome for the Gastroenterologist. ( Bui, QM; Ho, W; Lin, D, 2017) |
| "Aspirin has been extensively investigated in the context of the prevention of cardiovascular disease." | 2.52 | Can We Select Patients for Colorectal Cancer Prevention with Aspirin? ( Arber, N; Kraus, S; Sion, D, 2015) |
| "Colorectal cancer is a leading cause of cancer-related death globally, though in theory at least, it is eminently preventable in many cases." | 2.44 | Colorectal cancer prevention: choosing the most effective population strategy using bio-mathematical approaches. ( Luebeck, G; Renehan, AG, 2007) |
| "Chemoprevention of colorectal cancer involves the long-term use of pharmacologic agents that can prevent neoplasms from developing in the large bowel." | 2.43 | Low dose aspirin, COX-inhibition and chemoprevention of colorectal cancer. ( Benamouzig, R; Chaussade, S; Little, J; Uzzan, B, 2005) |
| "Nine trials with 150 familial adenomatous polyposis (FAP) and 24,143 population subjects met the inclusion criteria." | 2.42 | Non steroidal anti-inflammatory drugs (NSAID) and Aspirin for preventing colorectal adenomas and carcinomas. ( Asano, TK; McLeod, RS, 2004) |
| "Risk models for advanced colorectal neoplasms generally yielded modest discriminatory power, despite some variation in performance between models." | 1.51 | Head-to-Head Comparison of the Performance of 17 Risk Models for Predicting Presence of Advanced Neoplasms in Colorectal Cancer Screening. ( Balavarca, Y; Brenner, H; Hoffmeister, M; Peng, L; Weigl, K, 2019) |
| " Thus, we assessed the efficacy associated with different dosing regimens of aspirin and naproxen." | 1.51 | Intermittent Dosing Regimens of Aspirin and Naproxen Inhibit Azoxymethane-Induced Colon Adenoma Progression to Adenocarcinoma and Invasive Carcinoma. ( Biddick, L; Janakiram, NB; Li, Q; Lightfoot, S; Lubet, RA; Madka, V; Miller, MS; Mohammed, A; Rao, CV; Sei, S; Singh, A; Steele, VE; Suen, CS; Zhang, Y, 2019) |
| "The risk of postoperative hemorrhage following gastric ESD was higher in patients with antithrombotic therapy than in those without that therapy." | 1.39 | The postoperative bleeding rate and its risk factors in patients on antithrombotic therapy who undergo gastric endoscopic submucosal dissection. ( Edogawa, S; Harada, S; Higuchi, K; Kojima, Y; Ota, K; Takeuchi, T; Tokioka, S; Umegaki, E, 2013) |
| "Patients who underwent ESD for early gastric neoplasms at the National Cancer Center Hospital, Korea, between November 2008 and January 2011 were enrolled." | 1.38 | Aspirin use and bleeding risk after endoscopic submucosal dissection in patients with gastric neoplasms. ( Cho, SJ; Choi, IJ; Kim, CG; Kim, HJ; Kim, YW; Kwak, MH; Lee, JH; Lee, JY; Nam, BH; Ryu, KW, 2012) |
| "Five colon cancer and two adenoma cell lines, human ex vivo adenomas and normal colonic epithelium were treated with aspirin or sulindac combined with rhTRAIL." | 1.37 | TNF-related apoptosis-inducing ligand cooperates with NSAIDs via activated Wnt signalling in (pre)malignant colon cells. ( de Jong, S; de Vries, EG; Heijink, DM; Hollema, H; Jalving, M; Kleibeuker, JH; Koornstra, JJ; Koster, R; Oosterhuis, D; Sloots, IA, 2011) |
| "To prospectively examine the association between non-steroidal anti-inflammatory drugs (NSAIDs) use (including dose and dosage schedule) and the recurrence of colorectal adenomas among individuals who were diagnosed with an adenoma at entry into a clinical trial." | 1.32 | Non-steroidal anti-inflammatory drug use is associated with reduction in recurrence of advanced and non-advanced colorectal adenomas (United States). ( Albert, PS; Burt, R; Caan, B; Corle, D; Hasson, M; Iber, F; Kikendall, JW; Lance, P; Lanza, E; Paskett, E; Schatzkin, A; Shike, M; Tangrea, JA; Weissfeld, J; Woodson, K, 2003) |
| "For people with an increased risk of colorectal cancer, acetylsalicylic acid only has a partial effect and therefore endoscopic surveillance is still indicated." | 1.32 | [Prevention of colorectal cancer: acetylsalicyclic acid and cyclo-oxygenase-2 inhibitors are only partially effective]. ( de Vries, EG; Kleibeuker, JH, 2003) |
| "Colorectal cancer is the second leading cause of death from cancer in the United States." | 1.29 | G1 delay in cells overexpressing prostaglandin endoperoxide synthase-2. ( Beauchamp, RD; DuBois, RN; Shao, J; Sheng, H; Tsujii, M, 1996) |
| "Treatment with indomethacin, another PES inhibitor, also did not reduce the pulmonary BP metabolite:DNA adduct levels." | 1.27 | Effect of aspirin and indomethacin on the formation of benzo(a)pyrene-induced pulmonary adenomas and DNA adducts in A/HeJ mice. ( Adriaenssens, PI; Anderson, MW; Boorman, GA; Eling, TE; Sivarajah, K, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.59) | 18.7374 |
| 1990's | 19 (11.18) | 18.2507 |
| 2000's | 73 (42.94) | 29.6817 |
| 2010's | 52 (30.59) | 24.3611 |
| 2020's | 25 (14.71) | 2.80 |
| Authors | Studies |
|---|---|
| Ishikawa, H | 4 |
| Wang, Y | 2 |
| Boland, CR | 1 |
| Goel, A | 1 |
| Wodarz, D | 1 |
| Komarova, NL | 1 |
| Ji, YY | 1 |
| Jiang, TT | 1 |
| Sun, TK | 1 |
| Wang, ZD | 1 |
| Jodal, HC | 1 |
| Bretthauer, M | 3 |
| Kalager, M | 1 |
| Løberg, M | 1 |
| Barry, EL | 16 |
| Fedirko, V | 3 |
| Jin, Y | 1 |
| Liu, K | 2 |
| Mott, LA | 8 |
| Peacock, JL | 2 |
| Passarelli, MN | 4 |
| Baron, JA | 24 |
| Jones, DP | 2 |
| Zaman, FY | 1 |
| Orchard, SG | 1 |
| Haydon, A | 1 |
| Zalcberg, JR | 1 |
| Zaccari, P | 1 |
| Archibugi, L | 1 |
| Belfiori, G | 1 |
| Nista, E | 1 |
| dell'Anna, G | 1 |
| Crippa, S | 1 |
| Schepis, T | 1 |
| Tacelli, M | 1 |
| Aleotti, F | 1 |
| Petrone, MC | 1 |
| Mariani, A | 1 |
| Costamagna, G | 1 |
| Gasbarrini, A | 1 |
| Larghi, A | 1 |
| Falconi, M | 1 |
| Arcidiacono, PG | 1 |
| Capurso, G | 1 |
| Grancher, A | 2 |
| Michel, P | 2 |
| Di Fiore, F | 2 |
| Sefrioui, D | 2 |
| Szabó, B | 1 |
| Németh, K | 2 |
| Mészáros, K | 1 |
| Krokker, L | 1 |
| Likó, I | 1 |
| Saskői, É | 1 |
| Szabó, PT | 1 |
| Szücs, N | 1 |
| Czirják, S | 1 |
| Szalóki, G | 1 |
| Patócs, A | 1 |
| Butz, H | 1 |
| Yoshida, N | 1 |
| Otani, T | 1 |
| Goto, C | 3 |
| Matsuda, T | 3 |
| Takeuchi, Y | 1 |
| Sano, Y | 2 |
| Itoh, Y | 1 |
| Suzuki, S | 3 |
| Mutoh, M | 3 |
| Kowalczyk, M | 1 |
| Sigorski, D | 1 |
| Dyśko, Ł | 1 |
| Zieliński, E | 1 |
| Zupanovich Lucka, D | 1 |
| Klepacki, Ł | 1 |
| Nafisi, S | 1 |
| Randel, KR | 2 |
| Støer, NC | 1 |
| Veierød, MB | 1 |
| Hoff, G | 3 |
| Holme, Ø | 2 |
| Schult, AL | 1 |
| Botteri, E | 2 |
| Ma, Y | 1 |
| You, W | 1 |
| Cao, Y | 2 |
| He, X | 1 |
| Wang, J | 1 |
| Zhang, Y | 2 |
| Li, J | 2 |
| Barber, LE | 1 |
| Bertrand, KA | 1 |
| Sheehy, S | 1 |
| White, LF | 1 |
| Roy, HK | 2 |
| Rosenberg, L | 1 |
| Palmer, JR | 1 |
| Petrick, JL | 1 |
| Enciu, A | 1 |
| Loeschner, D | 1 |
| Alhallak, M | 1 |
| Kellner, G | 1 |
| Meyer, A | 1 |
| Lauten, A | 1 |
| Steinbrecher, A | 1 |
| Gerlach, R | 1 |
| Peng, L | 1 |
| Balavarca, Y | 1 |
| Weigl, K | 1 |
| Hoffmeister, M | 1 |
| Brenner, H | 2 |
| Mohammed, A | 1 |
| Janakiram, NB | 1 |
| Madka, V | 1 |
| Singh, A | 1 |
| Biddick, L | 1 |
| Li, Q | 1 |
| Lightfoot, S | 1 |
| Steele, VE | 1 |
| Lubet, RA | 1 |
| Suen, CS | 1 |
| Miller, MS | 1 |
| Sei, S | 1 |
| Rao, CV | 2 |
| Kwon, S | 1 |
| Chan, AT | 8 |
| Clapper, ML | 1 |
| Chang, WL | 1 |
| Cooper, HS | 1 |
| Uppal, K | 1 |
| Ma, C | 1 |
| Soualy, A | 1 |
| Deutsch, D | 1 |
| Benallaoua, M | 1 |
| Ait-Omar, A | 1 |
| Mary, F | 1 |
| Helfen, S | 1 |
| Boubaya, M | 1 |
| Levy, V | 1 |
| Benamouzig, R | 8 |
| Ghaddaf, AA | 1 |
| Aziz, M | 1 |
| Alomari, MS | 1 |
| Abdulhamid, AS | 1 |
| Alharbi, FA | 1 |
| Mullah, AN | 1 |
| Zaidi, SF | 1 |
| Veettil, SK | 2 |
| Kew, ST | 1 |
| Lim, KG | 2 |
| Phisalprapa, P | 2 |
| Kumar, S | 1 |
| Lee, YY | 1 |
| Chaiyakunapruk, N | 2 |
| Kane, AM | 1 |
| Liu, C | 1 |
| Fennell, LJ | 1 |
| McKeone, DM | 1 |
| Bond, CE | 1 |
| Pollock, PM | 1 |
| Young, G | 1 |
| Leggett, BA | 1 |
| Whitehall, VLJ | 1 |
| Brennan, CA | 1 |
| Nakatsu, G | 1 |
| Gallini Comeau, CA | 1 |
| Drew, DA | 2 |
| Glickman, JN | 1 |
| Schoen, RE | 1 |
| Garrett, WS | 1 |
| Chudy-Onwugaje, K | 1 |
| Huang, WY | 1 |
| Su, LJ | 1 |
| Purdue, MP | 1 |
| Johnson, CC | 1 |
| Wang, L | 1 |
| Katki, HA | 1 |
| Barry, KH | 1 |
| Berndt, SI | 1 |
| Wang, IE | 1 |
| Yi, S | 1 |
| Block, RC | 1 |
| Mousa, SA | 1 |
| Ching, SM | 1 |
| Saokaew, S | 1 |
| Zhang, D | 1 |
| Gangar, P | 1 |
| Rees, JR | 3 |
| Bresalier, RS | 10 |
| McKeown-Eyssen, G | 6 |
| Karagas, MR | 1 |
| Niikura, R | 1 |
| Yamada, A | 1 |
| Fujishiro, M | 1 |
| Tanaka, K | 1 |
| Matsuda, K | 1 |
| Saito, Y | 1 |
| Ohtsuka, K | 1 |
| Oda, I | 1 |
| Katada, C | 1 |
| Kato, M | 2 |
| Kida, M | 1 |
| Kobayashi, K | 1 |
| Hoteya, S | 1 |
| Horimatsu, T | 1 |
| Kodashima, S | 1 |
| Muto, M | 1 |
| Yamamoto, H | 1 |
| Ryozawa, S | 1 |
| Iwakiri, R | 1 |
| Kutsumi, H | 1 |
| Miyata, H | 1 |
| Haruma, K | 1 |
| Fujimoto, K | 1 |
| Uemura, N | 1 |
| Kaminishi, M | 1 |
| Shinozaki, T | 1 |
| Tajiri, H | 1 |
| Koike, K | 1 |
| Dekker, E | 1 |
| Kaminski, MF | 1 |
| Hull, MA | 2 |
| Sprange, K | 1 |
| Hepburn, T | 1 |
| Tan, W | 1 |
| Shafayat, A | 1 |
| Rees, CJ | 2 |
| Clifford, G | 1 |
| Logan, RF | 8 |
| Loadman, PM | 2 |
| Williams, EA | 1 |
| Whitham, D | 2 |
| Montgomery, AA | 2 |
| Dickson, I | 1 |
| Romstad, KMK | 1 |
| Frigstad, SO | 1 |
| de Lange, T | 1 |
| DeCensi, A | 1 |
| Gescher, A | 2 |
| Danış, N | 1 |
| Tekin, F | 1 |
| Calderazzo, S | 1 |
| Seufferlein, T | 1 |
| Ludwig, L | 1 |
| Dikopoulos, N | 1 |
| Mangold, J | 1 |
| Böck, W | 1 |
| Stolz, T | 1 |
| Eisenbach, T | 1 |
| Block, T | 1 |
| Kopp-Schneider, A | 1 |
| Czock, D | 1 |
| Tikk, K | 1 |
| Ahnen, DJ | 12 |
| Sandell, AC | 1 |
| Clifford, GM | 1 |
| Takeuchi, T | 1 |
| Ota, K | 1 |
| Harada, S | 1 |
| Edogawa, S | 1 |
| Kojima, Y | 1 |
| Tokioka, S | 1 |
| Umegaki, E | 1 |
| Higuchi, K | 1 |
| Wakabayashi, K | 2 |
| Hirata, K | 1 |
| Nakamura, T | 1 |
| Takeyama, I | 1 |
| Kawano, A | 1 |
| Gondo, N | 2 |
| Abe, T | 2 |
| Tokudome, S | 2 |
| Matsuura, N | 2 |
| Sakai, T | 2 |
| Saida, Y | 1 |
| Okamura, S | 1 |
| Tajika, M | 1 |
| Joh, T | 1 |
| Tanaka, S | 1 |
| Kudo, SE | 1 |
| Iimuro, M | 1 |
| Yukawa, T | 1 |
| Takayama, T | 1 |
| Sato, Y | 1 |
| Lee, K | 1 |
| Kitamura, S | 1 |
| Mizuno, M | 1 |
| Sugimoto, K | 1 |
| Kusunoki, M | 1 |
| Sung, JJ | 1 |
| Principi, M | 1 |
| De Censi, A | 1 |
| Ogawa, Y | 1 |
| Tominaga, T | 1 |
| Bradshaw, PT | 1 |
| Figueiredo, JC | 5 |
| Sandler, RS | 19 |
| Milne, GL | 2 |
| Kraus, S | 2 |
| Sion, D | 1 |
| Arber, N | 3 |
| Pommergaard, HC | 1 |
| Burcharth, J | 1 |
| Rosenberg, J | 1 |
| Raskov, H | 1 |
| Yip, WK | 1 |
| Bonetti, M | 1 |
| Cole, BF | 6 |
| Barcella, W | 1 |
| Wang, XV | 1 |
| Lazar, A | 1 |
| Gelber, RD | 1 |
| Zhao, TY | 1 |
| Tu, J | 1 |
| Cheng, DW | 1 |
| Gao, XK | 1 |
| Luo, H | 1 |
| Yan, BC | 1 |
| Xu, XL | 1 |
| Zhang, HL | 1 |
| Lu, XJ | 1 |
| Wang, YJ | 1 |
| Bui, QM | 1 |
| Lin, D | 1 |
| Ho, W | 1 |
| Chin, SM | 1 |
| Gilpin, KK | 1 |
| Parziale, M | 1 |
| Pond, E | 1 |
| Schuck, MM | 1 |
| Stewart, K | 1 |
| Flagg, M | 1 |
| Rawlings, CA | 1 |
| Backman, V | 1 |
| Carolan, PJ | 1 |
| Chung, DC | 2 |
| Colizzo, FP | 1 |
| Freedman, M | 1 |
| Gala, M | 1 |
| Garber, JJ | 1 |
| Huttenhower, C | 1 |
| Kedrin, D | 1 |
| Khalili, H | 1 |
| Kwon, DS | 1 |
| Markowitz, SD | 1 |
| Nishioka, NS | 1 |
| Richter, JM | 1 |
| Staller, K | 1 |
| Wang, M | 1 |
| Levine, AJ | 5 |
| Grau, MV | 9 |
| Midttun, O | 1 |
| Ueland, PM | 5 |
| Tsang, S | 3 |
| Munroe, D | 1 |
| Ali, I | 1 |
| Haile, RW | 11 |
| Wallace, K | 2 |
| Saibil, F | 5 |
| Ahnen, D | 2 |
| Munroe, DJ | 2 |
| Ali, IU | 2 |
| Ueland, P | 1 |
| Byers, T | 3 |
| Summers, RW | 5 |
| Bond, J | 1 |
| McKeown-Eyssen, GE | 4 |
| Gao, F | 1 |
| Liao, C | 1 |
| Liu, L | 1 |
| Tan, A | 1 |
| Mo, Z | 1 |
| Burn, J | 4 |
| Bishop, DT | 2 |
| Mecklin, JP | 2 |
| Macrae, F | 3 |
| Möslein, G | 1 |
| Olschwang, S | 2 |
| Bisgaard, ML | 2 |
| Ramesar, R | 2 |
| Eccles, D | 2 |
| Maher, ER | 2 |
| Bertario, L | 2 |
| Jarvinen, HJ | 1 |
| Lindblom, A | 2 |
| Evans, DG | 2 |
| Lubinski, J | 2 |
| Morrison, PJ | 2 |
| Ho, JW | 2 |
| Vasen, HF | 2 |
| Side, L | 2 |
| Thomas, HJ | 2 |
| Scott, RJ | 2 |
| Dunlop, M | 1 |
| Barker, G | 2 |
| Elliott, F | 2 |
| Jass, JR | 1 |
| Fodde, R | 3 |
| Lynch, HT | 2 |
| Mathers, JC | 3 |
| Gui, J | 2 |
| Halabi, S | 2 |
| Grainge, MJ | 5 |
| Chaussade, S | 7 |
| Burke, CA | 4 |
| Shen, L | 1 |
| Hamdan, R | 1 |
| Chen, X | 1 |
| Issa, JP | 1 |
| Yang, F | 1 |
| Jin, C | 1 |
| Fu, D | 1 |
| Topping, DL | 1 |
| Bird, AR | 1 |
| Young, GP | 1 |
| Morgan, G | 1 |
| Elwood, P | 1 |
| Sansbury, LB | 1 |
| Burke, C | 1 |
| Ho, GY | 1 |
| Xue, X | 1 |
| Cushman, M | 1 |
| Rohan, TE | 1 |
| Hazra, A | 1 |
| Selhub, J | 1 |
| Chao, WH | 1 |
| Hunter, DJ | 4 |
| Uzzan, B | 3 |
| Martin, A | 4 |
| Deyra, J | 4 |
| Little, J | 6 |
| Girard, B | 3 |
| Rufner, KL | 1 |
| Park, MK | 1 |
| Tweed, EM | 1 |
| Heijink, DM | 1 |
| Jalving, M | 1 |
| Oosterhuis, D | 1 |
| Sloots, IA | 1 |
| Koster, R | 1 |
| Hollema, H | 2 |
| Kleibeuker, JH | 3 |
| Koornstra, JJ | 1 |
| de Vries, EG | 3 |
| de Jong, S | 2 |
| Greenspan, EJ | 1 |
| Madigan, JP | 1 |
| Boardman, LA | 1 |
| Rosenberg, DW | 1 |
| Zubiaurre, L | 1 |
| Bujanda Fernández de Pierola, L | 1 |
| Gerdes, AM | 1 |
| Moeslein, G | 1 |
| Dunlop, MG | 1 |
| Hodgson, SV | 1 |
| Murday, V | 1 |
| Crawford, G | 1 |
| Movahedi, M | 1 |
| Pylvanainen, K | 1 |
| Wijnen, JT | 1 |
| Guijarro de Armas, MA | 1 |
| Vega Piñero, B | 1 |
| Pavón de Paz, I | 1 |
| Alameda Hernando, C | 1 |
| Monereo Megías, S | 1 |
| Cho, SJ | 1 |
| Choi, IJ | 1 |
| Kim, CG | 1 |
| Lee, JY | 1 |
| Nam, BH | 1 |
| Kwak, MH | 1 |
| Kim, HJ | 3 |
| Ryu, KW | 1 |
| Lee, JH | 1 |
| Kim, YW | 1 |
| Lee, SH | 1 |
| Shin, SJ | 1 |
| Park, DI | 1 |
| Kim, SE | 1 |
| Hong, SP | 1 |
| Hong, SN | 1 |
| Yang, DH | 1 |
| Lee, BI | 1 |
| Kim, YH | 1 |
| Kim, HS | 1 |
| Yang, SK | 1 |
| Kim, SH | 1 |
| Ferrández, A | 1 |
| Piazuelo, E | 1 |
| Castells, A | 1 |
| Thiagarajan, P | 1 |
| Jankowski, JA | 1 |
| Manzano, A | 1 |
| Pérez-Segura, P | 1 |
| Vendrell, M | 1 |
| Valero, R | 1 |
| Mercadal, J | 1 |
| Enseñat, J | 1 |
| Fábregas, N | 1 |
| Püllen, R | 1 |
| Dovjak, P | 1 |
| Poole, EM | 1 |
| Makar, KW | 1 |
| Ulrich, CM | 2 |
| Pennarun, B | 1 |
| Boersma-van Ek, W | 1 |
| Kruyt, FA | 1 |
| Bruno, A | 1 |
| Dovizio, M | 1 |
| Tacconelli, S | 1 |
| Patrignani, P | 1 |
| Pence, BC | 1 |
| Belasco, EJ | 1 |
| Lyford, CP | 1 |
| Jacobs, ET | 1 |
| Giuliano, AR | 1 |
| Roe, DJ | 1 |
| Guillén-Rodríguez, JM | 1 |
| Alberts, DS | 2 |
| Martínez, ME | 3 |
| Lin, HJ | 1 |
| Lakkides, KM | 1 |
| Keku, TO | 1 |
| Reddy, ST | 1 |
| Louie, AD | 1 |
| Kau, IH | 1 |
| Zhou, H | 1 |
| Gim, JS | 1 |
| Ma, HL | 1 |
| Matthies, CF | 1 |
| Dai, A | 1 |
| Huang, HF | 1 |
| Materi, AM | 1 |
| Lin, JH | 1 |
| Frankl, HD | 1 |
| Lee, ER | 1 |
| Hardy, SI | 1 |
| Herschman, HR | 1 |
| Henderson, BE | 1 |
| Kolonel, LN | 1 |
| Le Marchand, L | 1 |
| Garavito, RM | 1 |
| Smith, WL | 1 |
| Imperiale, TF | 1 |
| Budinger, S | 1 |
| Paskett, E | 2 |
| Keresztes, R | 1 |
| Petrelli, N | 1 |
| Pipas, JM | 1 |
| Karp, DD | 1 |
| Loprinzi, CL | 1 |
| Steinbach, G | 1 |
| Schilsky, R | 1 |
| Bresalier, R | 1 |
| Rothstein, R | 1 |
| Snover, DC | 2 |
| Church, TR | 2 |
| Allen, JI | 2 |
| Beach, M | 1 |
| Beck, GJ | 2 |
| Bond, JH | 2 |
| Greenberg, ER | 3 |
| Mandel, JS | 4 |
| Marcon, N | 2 |
| Pearson, L | 1 |
| van Stolk, RU | 1 |
| Perkins, S | 1 |
| Clarke, AR | 1 |
| Steward, W | 1 |
| Hassan, Y | 1 |
| O'Brien, TG | 2 |
| Fultz, KE | 1 |
| Babbar, N | 1 |
| Yerushalmi, H | 1 |
| Qu, N | 1 |
| Guo, Y | 1 |
| Boorman, D | 1 |
| Einspahr, J | 1 |
| Gerner, EW | 1 |
| Levenson, D | 1 |
| Jullian, E | 1 |
| Piednoir, B | 1 |
| Couturier, D | 2 |
| Coste, T | 2 |
| Zhang, Z | 1 |
| Ouyang, Q | 1 |
| Gan, H | 1 |
| Tangrea, JA | 1 |
| Albert, PS | 1 |
| Lanza, E | 2 |
| Woodson, K | 1 |
| Corle, D | 2 |
| Hasson, M | 1 |
| Burt, R | 1 |
| Caan, B | 2 |
| Iber, F | 1 |
| Kikendall, JW | 2 |
| Lance, P | 1 |
| Shike, M | 2 |
| Weissfeld, J | 1 |
| Schatzkin, A | 2 |
| Hawk, ET | 2 |
| Viner, JL | 2 |
| Giovannucci, EL | 3 |
| Schernhammer, ES | 1 |
| Colditz, GA | 2 |
| Willett, WC | 2 |
| Fuchs, CS | 3 |
| Asano, TK | 2 |
| McLeod, RS | 2 |
| Tranah, GJ | 2 |
| Ritt, M | 1 |
| Scovern, H | 1 |
| Schmiegel, W | 1 |
| Pox, C | 1 |
| Kroesen, A | 1 |
| Gill, S | 1 |
| Sinicrope, FA | 1 |
| Gondal, G | 1 |
| Grotmol, T | 1 |
| Hofstad, B | 1 |
| Eide, TJ | 1 |
| Raskov, HH | 1 |
| Beresford, SA | 1 |
| Johnson, KC | 1 |
| Ritenbaugh, C | 1 |
| Lasser, NL | 1 |
| Snetselaar, LG | 1 |
| Black, HR | 1 |
| Anderson, GL | 1 |
| Assaf, AR | 1 |
| Bassford, T | 1 |
| Bowen, D | 1 |
| Brunner, RL | 1 |
| Brzyski, RG | 1 |
| Chlebowski, RT | 1 |
| Gass, M | 1 |
| Harrigan, RC | 1 |
| Hays, J | 1 |
| Heber, D | 1 |
| Heiss, G | 1 |
| Hendrix, SL | 1 |
| Howard, BV | 1 |
| Hsia, J | 1 |
| Hubbell, FA | 1 |
| Jackson, RD | 1 |
| Kotchen, JM | 1 |
| Kuller, LH | 1 |
| LaCroix, AZ | 1 |
| Lane, DS | 1 |
| Langer, RD | 1 |
| Lewis, CE | 1 |
| Manson, JE | 1 |
| Margolis, KL | 1 |
| Mossavar-Rahmani, Y | 1 |
| Ockene, JK | 1 |
| Parker, LM | 1 |
| Perri, MG | 1 |
| Phillips, L | 1 |
| Prentice, RL | 1 |
| Robbins, J | 1 |
| Rossouw, JE | 1 |
| Sarto, GE | 1 |
| Stefanick, ML | 1 |
| Van Horn, L | 1 |
| Vitolins, MZ | 1 |
| Wactawski-Wende, J | 1 |
| Wallace, RB | 1 |
| Whitlock, E | 1 |
| Bertagnolli, MM | 1 |
| Eagle, CJ | 2 |
| Zauber, AG | 2 |
| Redston, M | 1 |
| Solomon, SD | 2 |
| Kim, K | 1 |
| Tang, J | 2 |
| Rosenstein, RB | 2 |
| Wittes, J | 2 |
| Hess, TM | 1 |
| Woloj, GM | 1 |
| Boisserie, F | 1 |
| Anderson, WF | 1 |
| Bagheri, D | 1 |
| Dewar, T | 1 |
| Foley, TR | 1 |
| Hoffman, N | 1 |
| Pruitt, RE | 1 |
| Saltzman, JR | 1 |
| Salzberg, B | 1 |
| Sylwestrowicz, T | 1 |
| Gordon, GB | 1 |
| Spicak, J | 1 |
| Rácz, I | 1 |
| Dite, P | 1 |
| Hajer, J | 1 |
| Zavoral, M | 1 |
| Lechuga, MJ | 1 |
| Gerletti, P | 1 |
| Macdonald, K | 1 |
| Bhadra, P | 1 |
| Fowler, R | 1 |
| Levin, B | 2 |
| Bhat, S | 1 |
| Hubner, RA | 4 |
| Muir, KR | 5 |
| Liu, JF | 4 |
| Grainge, M | 1 |
| Armitage, N | 1 |
| Shepherd, V | 1 |
| Popat, S | 1 |
| Houlston, RS | 4 |
| Levine, JS | 1 |
| Dubé, C | 1 |
| Rostom, A | 1 |
| Lewin, G | 1 |
| Tsertsvadze, A | 1 |
| Barrowman, N | 1 |
| Code, C | 1 |
| Sampson, M | 1 |
| Moher, D | 1 |
| Cen, YY | 1 |
| Renehan, AG | 1 |
| Luebeck, G | 1 |
| Flossmann, E | 1 |
| Rothwell, PM | 1 |
| Rothstein, RI | 1 |
| Robertson, DJ | 1 |
| Pearson, LH | 1 |
| Potter, JD | 2 |
| DuPont, AW | 1 |
| Arguedas, MR | 1 |
| Wilcox, CM | 2 |
| Logan, RFA | 1 |
| Chae, YK | 1 |
| Yun, JH | 1 |
| Shepherd, VC | 1 |
| Armitage, NC | 1 |
| Lundberg, GD | 1 |
| Adriaenssens, PI | 1 |
| Sivarajah, K | 1 |
| Boorman, GA | 1 |
| Eling, TE | 1 |
| Anderson, MW | 1 |
| Nelson, C | 1 |
| Wargovich, MJ | 1 |
| Chen, CD | 1 |
| Harris, C | 1 |
| Yang, E | 1 |
| Velasco, M | 1 |
| Giovannucci, E | 1 |
| Rimm, EB | 1 |
| Stampfer, MJ | 1 |
| Ascherio, A | 1 |
| Reddy, BS | 1 |
| Rivenson, A | 1 |
| Kelloff, G | 1 |
| Hawtin, PG | 1 |
| Hardcastle, JD | 1 |
| Lo, SV | 1 |
| Perry, HU | 1 |
| Lyons, R | 1 |
| Freeman, DH | 1 |
| Haile, R | 1 |
| Elder, DJ | 1 |
| Hague, A | 1 |
| Hicks, DJ | 1 |
| Paraskeva, C | 1 |
| DuBois, RN | 1 |
| Shao, J | 1 |
| Tsujii, M | 1 |
| Sheng, H | 1 |
| Beauchamp, RD | 1 |
| Peleg, II | 1 |
| Lubin, MF | 1 |
| Cotsonis, GA | 1 |
| Clark, WS | 1 |
| Weiss, HA | 1 |
| Forman, D | 1 |
| Freedman, LS | 1 |
| Tangrea, J | 1 |
| Cooper, MR | 1 |
| Marshall, JR | 1 |
| Murphy, PA | 1 |
| Selby, JV | 1 |
| Schade, RR | 1 |
| Burt, RW | 1 |
| Cahill, J | 1 |
| Duperron, C | 1 |
| Castonguay, A | 2 |
| McPherson, RS | 1 |
| Glober, GA | 1 |
| Galanko, JC | 1 |
| Murray, SC | 1 |
| Helm, JF | 1 |
| Woosley, JT | 1 |
| Thun, MJ | 1 |
| Barnes, CJ | 1 |
| Lee, M | 1 |
| Williamson, SL | 1 |
| Kartheuser, A | 1 |
| Coaker, J | 1 |
| Kooshkghazi, MD | 1 |
| García Rodríguez, LA | 1 |
| Huerta-Alvarez, C | 2 |
| García-Rodríguez, LA | 1 |
| Yao, R | 1 |
| Rioux, N | 1 |
| You, M | 1 |
| Bigler, J | 1 |
| Whitton, J | 1 |
| Lampe, JW | 1 |
| Fosdick, L | 1 |
| Bostick, RM | 1 |
| Yoon, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Assessment of the Effect of a Daily Chemoprevention by Low-dose Aspirin of New or Recurrent Colorectal Adenomas in Patients With Lynch Syndrome[NCT02813824] | Phase 3 | 852 participants (Anticipated) | Interventional | 2017-11-14 | Recruiting | ||
| Colorectal Cancer Screening in Norway: Pilot Study of a National Screening Programme With Randomised Comparison of Different Screening Strategies to Provide the Best Possible Service to the Population[NCT01538550] | 140,000 participants (Actual) | Interventional | 2012-03-31 | Active, not recruiting | |||
| Aspirin/Folate Prevention of Large Bowel Polyps[NCT00272324] | Phase 2/Phase 3 | 1,121 participants | Interventional | 1992-02-29 | Completed | ||
| A Clinical Trial Evaluating the Efficacy and Safety of a Combination Treatment Administered Over 3 Years in Patients at Risk of Experiencing Recurrence of Colorectal Adenomas[NCT00486512] | Phase 3 | 350 participants (Actual) | Interventional | 2007-06-30 | Terminated (stopped due to The overall program was terminated) | ||
| ASPIRED: ASPirin Intervention for the REDuction of Colorectal Cancer Risk[NCT02394769] | 180 participants (Actual) | Interventional | 2015-07-06 | Active, not recruiting | |||
| Prospective Study on Aspirin Efficacy in Reducing Colorectal Adenoma Recurrence[NCT00224679] | Phase 3 | 300 participants | Interventional | 1997-03-31 | Terminated | ||
| Comparison of Small Colorectal Polyp Removal Using Cold Endoscopic Mucosal Resection With Hot Endoscopic Mucosal Resection: a Pilot Study[NCT03000868] | 0 participants (Actual) | Interventional | 2016-12-01 | Withdrawn (stopped due to No participants were enrolled.) | |||
| Colorectal Adenoma Chemoprevention Trial Using Aspirin: A Phase III Study[NCT00002527] | Phase 3 | 635 participants (Actual) | Interventional | 1993-05-31 | Completed | ||
| Norwegian Colorectal Cancer Prevention Trial[NCT00119912] | 100,000 participants (Actual) | Interventional | 1999-01-31 | Active, not recruiting | |||
| [NCT00000611] | Phase 3 | 0 participants | Interventional | Completed | |||
| Prevention of Sporadic Colorectal Adenomas With Celecoxib[NCT00005094] | Phase 3 | 1,170 participants (Anticipated) | Interventional | 2000-03-31 | Completed | ||
| Celecoxib for the Treatment of Non-muscle Invasive Bladder Cancer[NCT02343614] | Phase 2 | 58 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| Clinical Protocol For a Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Celecoxib (SC-58635) In The Prevention of Colorectal Sporadic Adenomatous Polyps (PRESAP)[NCT00141193] | Phase 3 | 1,561 participants (Actual) | Interventional | 2001-02-28 | Completed | ||
| Combined Analyses and Long-term Follow-up in the Two Norwegian Homocysteine-Lowering B-Vitamin Trials NORVIT and WENBIT[NCT00671346] | 6,839 participants (Anticipated) | Observational | 1998-12-31 | Active, not recruiting | |||
| [NCT00005182] | 50,000 participants (Actual) | Observational | 1985-12-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Measured using liquid chromatography/mass spectrometry (NCT02394769)
Timeframe: 8-12 weeks
| Intervention | ng/mg cr (Mean) | ||
|---|---|---|---|
| Baseline urinary PGE-M | Post-intervention urinary PGE-M | Change in urinary PGE-M | |
| Low Dose Aspirin | 17.7 | 13.1 | -4.6 |
| Placebo (For Aspirin) | 15.5 | 16.4 | 0.8 |
| Standard Dose Aspirin | 14.3 | 9.4 | -4.9 |
33 reviews available for aspirin and Adenoma
| Article | Year |
|---|---|
Non-aspirin non-steroidal anti-inflammatory drugs in colorectal cancer: a review of clinical studies.
Topics: Adenoma; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neop | 2022 |
Colorectal cancer chemoprevention: is aspirin still in the game?
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chemoprevention; Colorectal Neoplasms; Hu | 2022 |
Chemoprevention of colorectal cancer in general population and high-risk population: a systematic review and network meta-analysis.
Topics: Adenoma; Aspirin; Calcium; Chemoprevention; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Human | 2023 |
Dysplastic Aberrant Crypt Foci: Biomarkers of Early Colorectal Neoplasia and Response to Preventive Intervention.
Topics: Aberrant Crypt Foci; Adenoma; Adenomatous Polyposis Coli Protein; Animals; Antineoplastic Agents; As | 2020 |
Influence of aspirin on prevention of colorectal cancer: an updated systematic review and meta-analysis of randomized controlled trials.
Topics: Adenoma; Aspirin; Colorectal Neoplasms; Humans; Incidence; Randomized Controlled Trials as Topic | 2021 |
Very-low-dose aspirin and surveillance colonoscopy is cost-effective in secondary prevention of colorectal cancer in individuals with advanced adenomas: network meta-analysis and cost-effectiveness analysis.
Topics: Adenoma; Aspirin; Colonoscopy; Colorectal Neoplasms; Cost-Benefit Analysis; Humans; Network Meta-Ana | 2021 |
Aspirin and omega-3 polyunsaturated fatty acid use and their interaction in cardiovascular diseases and colorectal adenomas.
Topics: Adenoma; Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Dietary Supplements; Docosahexaenoi | 2022 |
Effects of aspirin and non-aspirin nonsteroidal anti-inflammatory drugs on the incidence of recurrent colorectal adenomas: a systematic review with meta-analysis and trial sequential analysis of randomized clinical trials.
Topics: Adenoma; Anti-Inflammatory Agents; Aspirin; Colorectal Neoplasms; Humans; Incidence; Neoplasm Recurr | 2017 |
[Aspirin and colorectal cancer].
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Class I Phosphat | 2018 |
Can We Select Patients for Colorectal Cancer Prevention with Aspirin?
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers; Colonic Polyps; Colorectal Ne | 2015 |
The Efficacy of Aspirin in Preventing the Recurrence of Colorectal Adenoma: a Renewed Meta-Analysis of Randomized Trials.
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Humans; Neoplasm Re | 2016 |
Approach to Lynch Syndrome for the Gastroenterologist.
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma; Colectomy; Colonoscopy; Colore | 2017 |
The effect of aspirin in the recurrence of colorectal adenomas: a meta-analysis of randomized controlled trials.
Topics: Adenoma; Aspirin; Colorectal Neoplasms; Cyclooxygenase Inhibitors; Humans; Neoplasm Recurrence, Loca | 2009 |
Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials.
Topics: Adenoma; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Colorectal | 2009 |
Clinical inquiries. Is aspirin effective for primary prevention of colon cancer?
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Neoplasms; Colorectal Neoplasms; | 2010 |
Aspirin and the prevention of colorectal cancer.
Topics: Adenoma; Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Ne | 2012 |
Aspirin and NSAIDs; benefits and harms for the gut.
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Cardiovascular Disease | 2012 |
Colorectal cancer chemoprevention: is this the future of colorectal cancer prevention?
Topics: Adenoma; Adenomatous Polyposis Coli; Adult; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspiri | 2012 |
Mechanisms of the antitumoural effects of aspirin in the gastrointestinal tract.
Topics: Adenoma; Anticarcinogenic Agents; Aspirin; Blood Platelets; Cyclooxygenase 1; Cyclooxygenase 2; Cycl | 2012 |
Nonsteroidal anti-inflammatory drugs and aspirin for the prevention of colorectal adenomas and cancer: a systematic review.
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Humans; Neoplastic | 2004 |
Non steroidal anti-inflammatory drugs (NSAID) and Aspirin for preventing colorectal adenomas and carcinomas.
Topics: Adenoma; Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma; Co | 2004 |
Colorectal cancer prevention: is an ounce of prevention worth a pound of cure?
Topics: Adenoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Calcium | 2005 |
Low dose aspirin, COX-inhibition and chemoprevention of colorectal cancer.
Topics: Adenoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Case-Co | 2005 |
[Non-steroidal anti-inflammatory agents and prevention of colorectal adenomas and carcinomas].
Topics: Adenoma; Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; | 2006 |
Clinical practice. Adenomatous polyps of the colon.
Topics: Adenoma; Adenomatous Polyps; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Neoplasms; Co | 2006 |
The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force.
Topics: Adenoma; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Colonic P | 2007 |
Colorectal cancer prevention: choosing the most effective population strategy using bio-mathematical approaches.
Topics: Adenoma; Aspirin; Colorectal Neoplasms; Feeding Behavior; Female; Humans; Male; Mass Screening; Mode | 2007 |
Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies.
Topics: Adenoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Colorectal | 2007 |
Aspirin chemoprevention in patients with increased risk for colorectal cancer: a cost-effectiveness analysis.
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cohort Studies; Colonoscopy; Colorectal N | 2007 |
Routine aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer: recommendation statement.
Topics: Adenoma; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Polyps; Colorectal Neoplas | 2007 |
Aspirin and other nonsteroidal anti-inflammatory agents in the prevention of colorectal cancer.
Topics: Adenocarcinoma; Adenoma; Adenomatous Polyposis Coli; Adult; Animals; Anti-Inflammatory Agents, Non-S | 1996 |
Aspirin, non-steroidal anti-inflammatory drugs and protection from colorectal cancer: a review of the epidemiological evidence.
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Colorectal Neoplasm | 1996 |
Aspirin and gastrointestinal cancer.
Topics: Adenoma; Adenomatous Polyposis Coli; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinoge | 1997 |
42 trials available for aspirin and Adenoma
| Article | Year |
|---|---|
[Aspirin for Chemoprevention of Colorectal Adenoma and Cancer].
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chemoprevention; Cohort Studies; Colorect | 2021 |
Plasma Metabolomics Analysis of Aspirin Treatment and Risk of Colorectal Adenomas.
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Colorectal Neopl | 2022 |
Metabolomics Analysis of Aspirin's Effects in Human Colon Tissue and Associations with Adenoma Risk.
Topics: Adenoma; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Colon; Colore | 2020 |
Effect of chemoprevention by low-dose aspirin of new or recurrent colorectal adenomas in patients with Lynch syndrome (AAS-Lynch): study protocol for a multicenter, double-blind, placebo-controlled randomized controlled trial.
Topics: Adenoma; Adult; Aspirin; Chemoprevention; Colorectal Neoplasms; Colorectal Neoplasms, Hereditary Non | 2020 |
Risk of basal cell carcinoma in a randomized clinical trial of aspirin and folic acid for the prevention of colorectal adenomas.
Topics: Adenoma; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma, Basal Cell; Colorectal N | 2018 |
Eicosapentaenoic acid and aspirin, alone and in combination, for the prevention of colorectal adenomas (seAFOod Polyp Prevention trial): a multicentre, randomised, double-blind, placebo-controlled, 2 × 2 factorial trial.
Topics: Adenoma; Aged; Anticarcinogenic Agents; Aspirin; Colonoscopy; Colorectal Neoplasms; Double-Blind Met | 2018 |
Effect of a Single Aspirin Dose Prior to Fecal Immunochemical Testing on Test Sensitivity for Detecting Advanced Colorectal Neoplasms: A Randomized Clinical Trial.
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Aspirin; Colorectal Neoplasms; Double-Blind Method; Early D | 2019 |
Body Composition and Aspirin Dose for Colorectal Adenoma Prevention in a Randomized Clinical Trial.
Topics: Adenoma; Aged; Aspirin; Body Composition; Colorectal Neoplasms; Female; Humans; Male; Middle Aged; R | 2019 |
A randomized controlled trial of eicosapentaenoic acid and/or aspirin for colorectal adenoma prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme (The seAFOod Polyp Prevention Trial): study protocol for a randomized cont
Topics: Adenoma; Aged; Anticarcinogenic Agents; Aspirin; Biomarkers, Tumor; Clinical Protocols; Colonoscopy; | 2013 |
Preventive effects of low-dose aspirin on colorectal adenoma growth in patients with familial adenomatous polyposis: double-blind, randomized clinical trial.
Topics: Adenoma; Adenomatous Polyposis Coli; Adult; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogeni | 2013 |
The preventive effects of low-dose enteric-coated aspirin tablets on the development of colorectal tumours in Asian patients: a randomised trial.
Topics: Adenocarcinoma; Adenoma; Adult; Aged; Alcohol Drinking; Anticarcinogenic Agents; Aspirin; Colonic Ne | 2014 |
Urinary metabolites of prostanoids and risk of recurrent colorectal adenomas in the Aspirin/Folate Polyp Prevention Study (AFPPS).
Topics: Adenoma; Administration, Oral; Aged; Aspirin; Chromatography, Gas; Chromatography, Liquid; Colonosco | 2015 |
Aspirin, Calcitriol, and Calcium Do Not Prevent Adenoma Recurrence in a Randomized Controlled Trial.
Topics: Adenoma; Adult; Aged; Aspirin; Calcitriol; Calcium; Chemoprevention; Colectomy; Colorectal Neoplasms | 2016 |
ASPirin Intervention for the REDuction of colorectal cancer risk (ASPIRED): a study protocol for a randomized controlled trial.
Topics: Adenoma; Adolescent; Adult; Aged; Aged, 80 and over; Anticarcinogenic Agents; Aspirin; Biomarkers, T | 2017 |
Vitamins B2, B6, and B12 and risk of new colorectal adenomas in a randomized trial of aspirin use and folic acid supplementation.
Topics: Adenoma; Alcohol Drinking; Aspirin; Chemoprevention; Colorectal Neoplasms; Double-Blind Method; Fema | 2008 |
MTHFR genotype and colorectal adenoma recurrence: data from a double-blind placebo-controlled clinical trial.
Topics: Adenoma; Alleles; Aspirin; Chi-Square Distribution; Colorectal Neoplasms; Double-Blind Method; Femal | 2008 |
Colorectal adenomas in a randomized folate trial: the role of baseline dietary and circulating folate levels.
Topics: Adenoma; Aspirin; Colonoscopy; Colorectal Neoplasms; Confidence Intervals; Diet; Female; Folic Acid; | 2008 |
Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome.
Topics: Adenoma; Adult; Aged; Aspirin; Carcinoma; Colorectal Neoplasms; Colorectal Neoplasms, Hereditary Non | 2008 |
Nonsteroidal anti-inflammatory drug use after 3 years of aspirin use and colorectal adenoma risk: observational follow-up of a randomized study.
Topics: Adenoma; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Colonoscop | 2009 |
Folic acid and risk of prostate cancer: results from a randomized clinical trial.
Topics: Adenoma; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neopl | 2009 |
Global DNA hypomethylation (LINE-1) in the normal colon and lifestyle characteristics and dietary and genetic factors.
Topics: Adenoma; Alcohol Drinking; Aspirin; Colon; Colonic Polyps; Colonoscopy; Colorectal Neoplasms; CpG Is | 2009 |
Cyclooxygenase-2 polymorphisms, aspirin treatment, and risk for colorectal adenoma recurrence--data from a randomized clinical trial.
Topics: Adenoma; Aged; Aspirin; Cohort Studies; Colorectal Neoplasms; Cyclooxygenase 2; Cyclooxygenase 2 Inh | 2009 |
Cyclooxygenase-2 expression and recurrence of colorectal adenomas: effect of aspirin chemoprevention.
Topics: Adenoma; Adolescent; Adult; Aged; Anticarcinogenic Agents; Aspirin; Biomarkers, Tumor; Colorectal Ne | 2010 |
Baseline plasma total homocysteine and adenoma recurrence: results from a double blind randomized clinical trial of aspirin and folate supplementation.
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Aspirin; Colorectal Neoplasms; Double-Blind Method; Folic A | 2010 |
Prevention by daily soluble aspirin of colorectal adenoma recurrence: 4-year results of the APACC randomised trial.
Topics: Adenoma; Adenomatous Polyps; Aged; Aspirin; Colonoscopy; Colorectal Neoplasms; Cyclooxygenase Inhibi | 2012 |
Variants downstream of the ornithine decarboxylase gene influence risk of colorectal adenoma and aspirin chemoprevention.
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cohort Studies; Colorectal Neoplasms; Fem | 2011 |
Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial.
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chemoprevention; Colorectal Neoplasms, He | 2011 |
CYP2C9 variants increase risk of colorectal adenoma recurrence and modify associations with smoking but not aspirin treatment.
Topics: Adenoma; Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Chemoprevention; Colorectal Neoplasms; Cytoch | 2013 |
Baseline dietary fiber intake and colorectal adenoma recurrence in the wheat bran fiber randomized trial.
Topics: Adenoma; Aged; Aspirin; Colorectal Neoplasms; Dietary Fiber; Educational Status; Exercise; Female; F | 2002 |
A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer.
Topics: Adenoma; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Polyps; Colonoscopy; | 2003 |
A randomized trial of aspirin to prevent colorectal adenomas.
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Polyps; Colonoscopy; Colorectal N | 2003 |
Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial.
Topics: Adenoma; Aspirin; Colorectal Neoplasms; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neopla | 2003 |
Low-fat dietary pattern and risk of colorectal cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial.
Topics: Adenoma; Aged; Aspirin; Colonic Polyps; Colorectal Neoplasms; Diet, Fat-Restricted; Estrogen Replace | 2006 |
Celecoxib for the prevention of sporadic colorectal adenomas.
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovas | 2006 |
Celecoxib for the prevention of sporadic colorectal adenomas.
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovas | 2006 |
Celecoxib for the prevention of sporadic colorectal adenomas.
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovas | 2006 |
Celecoxib for the prevention of sporadic colorectal adenomas.
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovas | 2006 |
Celecoxib for the prevention of colorectal adenomatous polyps.
Topics: Adenoma; Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal | 2006 |
Celecoxib for the prevention of colorectal adenomatous polyps.
Topics: Adenoma; Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal | 2006 |
Celecoxib for the prevention of colorectal adenomatous polyps.
Topics: Adenoma; Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal | 2006 |
Celecoxib for the prevention of colorectal adenomatous polyps.
Topics: Adenoma; Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal | 2006 |
Genetic variants of UGT1A6 influence risk of colorectal adenoma recurrence.
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Female; Genetic Pre | 2006 |
Folic acid for the prevention of colorectal adenomas: a randomized clinical trial.
Topics: Adenoma; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chi-Square Distribution; Col | 2007 |
Folic acid for the prevention of colorectal adenomas: a randomized clinical trial.
Topics: Adenoma; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chi-Square Distribution; Col | 2007 |
Folic acid for the prevention of colorectal adenomas: a randomized clinical trial.
Topics: Adenoma; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chi-Square Distribution; Col | 2007 |
Folic acid for the prevention of colorectal adenomas: a randomized clinical trial.
Topics: Adenoma; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chi-Square Distribution; Col | 2007 |
Polymorphisms in PTGS1, PTGS2 and IL-10 do not influence colorectal adenoma recurrence in the context of a randomized aspirin intervention trial.
Topics: Adenoma; Aspirin; Colorectal Neoplasms; Cyclooxygenase 1; Cyclooxygenase 2; Female; Follow-Up Studie | 2007 |
Aspirin and folic acid for the prevention of recurrent colorectal adenomas.
Topics: Adenoma; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chemotherapy, Adjuvant; Colo | 2008 |
Effect of aspirin and non-steroidal anti-inflammatory drugs on colorectal adenomas: case-control study of subjects participating in the Nottingham faecal occult blood screening programme.
Topics: Acetaminophen; Adenoma; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies | 1993 |
The polyp prevention trial I: rationale, design, recruitment, and baseline participant characteristics.
Topics: Adenoma; Adenomatous Polyps; Adult; Aspirin; Colonic Neoplasms; Colonic Polyps; Colonoscopy; Demogra | 1996 |
APACC, a French prospective study on aspirin efficacy in reducing colorectal adenoma recurrence: design and baseline findings.
Topics: Adenoma; Administration, Oral; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colono | 2001 |
95 other studies available for aspirin and Adenoma
| Article | Year |
|---|---|
Aspirin's effect on kinetic parameters of cells contributes to its role in reducing incidence of advanced colorectal adenomas, shown by a multiscale computational study.
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Humans; Incidence; | 2022 |
Letter: long-term colorectal cancer incidence and mortality after adenoma removal associated with heritable factors, colonoscopic surveillance and aspirin.
Topics: Adenoma; Aspirin; Colonoscopy; Colorectal Neoplasms; Humans; Incidence; Risk Factors | 2022 |
Letter: long-term colorectal cancer incidence and mortality after adenoma removal associated with heritable factors, colonoscopic surveillance and aspirin-authors' reply.
Topics: Adenoma; Aspirin; Colonoscopy; Colorectal Neoplasms; Humans; Incidence | 2022 |
Risk factors for the occurrence of ampullary tumors: A case-control study.
Topics: Adenoma; Ampulla of Vater; Aspirin; Carcinoma; Case-Control Studies; Common Bile Duct Neoplasms; Duo | 2022 |
Aspirin Mediates Its Antitumoral Effect Through Inhibiting PTTG1 in Pituitary Adenoma.
Topics: Adenoma; Aspirin; Decitabine; Humans; Mixed Function Oxygenases; Pituitary Neoplasms; Proto-Oncogene | 2022 |
Aspirin-Mediated Prevention of Colorectal Adenomas Recurrence is Affected by Blood Biochemistry and Nutritional Intake.
Topics: Adenoma; Aspirin; Colorectal Neoplasms; Eating; Female; Humans; Male; Triglycerides | 2022 |
The Effect of Low Doses of Acetylsalicylic Acid on the Occurrence of Rectal Aberrant Crypt Foci.
Topics: Aberrant Crypt Foci; Adenoma; Aspirin; Colorectal Neoplasms; Humans; Rectum | 2022 |
Association between use of low-dose aspirin and detection of colorectal polyps and cancer in a screening setting.
Topics: Adenoma; Aspirin; Colonic Polyps; Colonoscopy; Colorectal Neoplasms; Early Detection of Cancer; Huma | 2023 |
Aspirin and nonaspirin nonsteroidal antiinflammatory drug use and occurrence of colorectal adenoma in Black American women.
Topics: Acetaminophen; Adenoma; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Black or African Am | 2023 |
Management and risk of postoperative bleeding in patients with low-dose antiplatelet aspirin medication during endoscopic endonasal surgery for pituitary adenomas.
Topics: Adenoma; Aspirin; Humans; Pituitary Neoplasms; Postoperative Hemorrhage; Retrospective Studies; Trea | 2023 |
Head-to-Head Comparison of the Performance of 17 Risk Models for Predicting Presence of Advanced Neoplasms in Colorectal Cancer Screening.
Topics: Adenoma; Age Factors; Aged; Alcohol Drinking; Anti-Inflammatory Agents, Non-Steroidal; Area Under Cu | 2019 |
Intermittent Dosing Regimens of Aspirin and Naproxen Inhibit Azoxymethane-Induced Colon Adenoma Progression to Adenocarcinoma and Invasive Carcinoma.
Topics: Adenocarcinoma; Adenoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Azoxymethane; Ca | 2019 |
Extracting the benefits of berberine for colorectal cancer.
Topics: Adenoma; Antineoplastic Agents, Phytogenic; Aspirin; Berberine; Cardiovascular Diseases; Case-Contro | 2020 |
Aspirin reduces the incidence of metastasis in a pre-clinical study of Braf mutant serrated colorectal neoplasia.
Topics: Adenoma; Animals; Aspirin; Colorectal Neoplasms; Disease Models, Animal; Female; Incidence; Male; Mi | 2021 |
Aspirin Modulation of the Colorectal Cancer-Associated Microbe Fusobacterium nucleatum.
Topics: Adenoma; Animals; Aspirin; Bacteria; Carcinogenesis; Cell Transformation, Neoplastic; Colon; Colorec | 2021 |
Aspirin, ibuprofen, and reduced risk of advanced colorectal adenoma incidence and recurrence and colorectal cancer in the PLCO Cancer Screening Trial.
Topics: Adenoma; Aged; Aspirin; Colorectal Neoplasms; Early Detection of Cancer; Female; Humans; Ibuprofen; | 2021 |
The Effects of Direct Oral Anticoagulants, Warfarin, Aspirin and Thienopyridine on the Performance of Immunochemical, Faecal, Occult Blood Tests.
Topics: Adenoma; Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Case-Control Studie | 2019 |
Take a pill for no more polyps: is it that simple?
Topics: Adenoma; Aspirin; Colorectal Neoplasms; Double-Blind Method; Eicosapentaenoic Acid; Humans; Polyps | 2018 |
No risk reduction of colorectal adenoma with aspirin or eicosapentaenoic acid.
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Double-Blind Method | 2019 |
Effects of Oral Anticoagulants and Aspirin on Performance of Fecal Immunochemical Tests in Colorectal Cancer Screening.
Topics: Adenoma; Administration, Oral; Aged; Anticoagulants; Aspirin; Colonoscopy; Colorectal Neoplasms; Cro | 2019 |
An Abstract Provides "seAFOod" for Thought.
Topics: Adenoma; Aspirin; Colorectal Neoplasms; Double-Blind Method; Eicosapentaenoic Acid; Fatty Acids, Ome | 2019 |
Eicosapentaenoic acid and aspirin for colorectal adenomas.
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Double-Blind Method | 2019 |
The postoperative bleeding rate and its risk factors in patients on antithrombotic therapy who undergo gastric endoscopic submucosal dissection.
Topics: Adenoma; Aged; Anti-Ulcer Agents; Anticoagulants; Aspirin; Carcinoma; Case-Control Studies; Clopidog | 2013 |
Is aspirin for colorectal cancer prevention on the prime time yet?
Topics: Adenocarcinoma; Adenoma; Anticarcinogenic Agents; Aspirin; Colonic Neoplasms; Cyclooxygenase Inhibit | 2014 |
Prevention of colorectal adenomas.
Topics: Adenoma; Aspirin; Colorectal Neoplasms; Estrogen Receptor alpha; Estrogen Receptor beta; Humans; Lig | 2015 |
Sellar and parasellar tumor removal without discontinuing antithrombotic therapy.
Topics: Adenoma; Aged; Aspirin; Central Nervous System Cysts; Clopidogrel; Female; Fibrinolytic Agents; Huma | 2015 |
Subpopulation Treatment Effect Pattern Plot (STEPP) analysis for continuous, binary, and count outcomes.
Topics: Adenoma; Aspirin; Biomarkers, Tumor; Colorectal Neoplasms; Data Interpretation, Statistical; Folic A | 2016 |
Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome.
Topics: Adenoma; Aspirin; Colorectal Neoplasms; Colorectal Neoplasms, Hereditary Nonpolyposis; Confounding F | 2009 |
Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome.
Topics: Adenoma; Aspirin; Colorectal Neoplasms; Colorectal Neoplasms, Hereditary Nonpolyposis; Humans; Starc | 2009 |
Could recommendations about aspirin prophylaxis enhance colorectal cancer screening programmes?
Topics: Adenoma; Aspirin; Colorectal Neoplasms; Early Detection of Cancer; Humans; Practice Guidelines as To | 2009 |
Antagonistic effects of aspirin and folic acid on inflammation markers and subsequent risk of recurrent colorectal adenomas.
Topics: Adenoma; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers; C-Reactive Protein; Col | 2009 |
Uracil misincorporation into DNA and folic acid supplementation.
Topics: Adenoma; Aged; Alcohol Drinking; Aspirin; Colonoscopy; Colorectal Neoplasms; Dietary Supplements; DN | 2010 |
COX-2 expression in adenoma: an imperfect marker for chemoprevention.
Topics: Adenoma; Anticarcinogenic Agents; Aspirin; Biomarkers, Tumor; Colorectal Neoplasms; Cyclooxygenase 2 | 2010 |
TNF-related apoptosis-inducing ligand cooperates with NSAIDs via activated Wnt signalling in (pre)malignant colon cells.
Topics: Adenoma; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Apoptosis; Asp | 2011 |
Ibuprofen inhibits activation of nuclear {beta}-catenin in human colon adenomas and induces the phosphorylation of GSK-3{beta}.
Topics: Adenoma; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; beta Catenin; Blotting, West | 2011 |
Cancer: do aspirin and other NSAIDs protect against colorectal cancer?
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Dose-Response Relat | 2011 |
[Aspirin in the prevention of colorectal cancer].
Topics: Adenoma; Aspirin; Colorectal Neoplasms; Cyclooxygenase Inhibitors; Humans | 2011 |
[Thyrotoxicosis induced by subacute thyroiditis after surgery for a thyrotropinoma].
Topics: Adenoma; Adult; Aspirin; Female; Humans; Magnetic Resonance Imaging; Octreotide; Pituitary Gland, An | 2012 |
Aspirin use and bleeding risk after endoscopic submucosal dissection in patients with gastric neoplasms.
Topics: Adenocarcinoma; Adenoma; Aged; Aspirin; Cardiovascular Diseases; Female; Gastric Mucosa; Gastrointes | 2012 |
[Korean guidelines for colonoscopic polypectomy].
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Polyps; Colonoscopy; Colorectal N | 2012 |
[Cerebrovascular accident with haemorrhagic transformation in a patient on antiplatelet treatment subjected to surgery of a hypophyseal macroadenoma].
Topics: Adenoma; Aphasia, Broca; Aspirin; Cerebellum; Cerebral Hemorrhage; Craniotomy; Disease Progression; | 2012 |
[Journal club].
Topics: Adenoma; Adenomatous Polyps; Anticoagulants; Aspirin; Coffee; Colonic Polyps; Colonoscopy; Colorecta | 2012 |
Targeting FLIP and Mcl-1 using a combination of aspirin and sorafenib sensitizes colon cancer cells to TRAIL.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenoma; Antineoplastic Agents; Apoptosis; Asp | 2013 |
Combination aspirin and/or calcium chemoprevention with colonoscopy in colorectal cancer prevention: cost-effectiveness analyses.
Topics: Adenoma; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Calcium; Cohort Studies; Col | 2013 |
Prostaglandin H synthase 2 variant (Val511Ala) in African Americans may reduce the risk for colorectal neoplasia.
Topics: Adenoma; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Black People; Ca | 2002 |
Aspirin and the prevention of colorectal cancer.
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Humans; Secondary P | 2003 |
Age-related difference in susceptibility of Apc(Min/+) mice towards the chemopreventive efficacy of dietary aspirin and curcumin.
Topics: Adenoma; Administration, Oral; Aging; Animals; Anticarcinogenic Agents; Aspirin; Curcumin; Female; G | 2003 |
Aspirin and the prevention of colorectal cancer.
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bias; Colonoscopy; Colorectal Neoplasms; | 2003 |
Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene.
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Alleles; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; | 2003 |
Aspirin cuts return of precursor to colorectal cancer.
Topics: Adenoma; Aspirin; Colorectal Neoplasms; Humans; Isoenzymes; Treatment Outcome; United States | 2003 |
[Effects of NaBT and NSAIDs on colorectal adenoma-carcinoma cells].
Topics: Adenocarcinoma; Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Butyrates; Cel | 2003 |
Non-steroidal anti-inflammatory drug use is associated with reduction in recurrence of advanced and non-advanced colorectal adenomas (United States).
Topics: Adenoma; Adenomatous Polyps; Aged; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; As | 2003 |
Aspirin: still learning about the wonder drug.
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Colorectal Neopl | 2003 |
[Prevention of colorectal cancer: acetylsalicyclic acid and cyclo-oxygenase-2 inhibitors are only partially effective].
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Cyclooxygenase 2; C | 2003 |
A prospective study of aspirin use and the risk for colorectal adenoma.
Topics: Adenoma; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Dose-R | 2004 |
Aspirin prevention of colorectal cancer: more or less?
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Drug Administration | 2004 |
Summaries for patients. Relationships between aspirin dose and colorectal adenomas.
Topics: Adenoma; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Dose-R | 2004 |
[Chemopreventive agents in colorectal cancer].
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovas | 2003 |
Use of aspirin and its effect on adenoma risk.
Topics: Adenoma; Aspirin; Cohort Studies; Colorectal Neoplasms; Female; Humans; Risk Factors; United States | 2004 |
A prospective study of genetic polymorphisms in the cytochrome P-450 2C9 enzyme and the risk for distal colorectal adenoma.
Topics: Adenoma; Adult; Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Case-Control Studies; Colorectal Neopl | 2004 |
Aspirin for persons at higher risk for colorectal neoplasia.
Topics: Adenoma; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Dose-Respons | 2004 |
Aspirin use and risk for colorectal adenoma.
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Humans; Risk Factor | 2004 |
[Ulcerative colitis. Cancer prevention].
Topics: Adenoma; Adenomatous Polyposis Coli; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biopsy | 2004 |
Genetic variants in the UGT1A6 enzyme, aspirin use, and the risk of colorectal adenoma.
Topics: Adenoma; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Colonoscopy; | 2005 |
Lifestyle-related risk factors and chemoprevention for colorectal neoplasia: experience from the large-scale NORCCAP screening trial.
Topics: Adenoma; Age Distribution; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chemoprevention; | 2005 |
Interaction of calcium supplementation and nonsteroidal anti-inflammatory drugs and the risk of colorectal adenomas.
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Calcium; Calcium, Dietary; Colorectal Neo | 2005 |
Ornithine decarboxylase polymorphism modification of response to aspirin treatment for colorectal adenoma prevention.
Topics: Adenoma; Adenomatous Polyposis Coli; Aged; Alanine; Anticarcinogenic Agents; Aspirin; Colorectal Neo | 2006 |
Summaries for patients. Aspirin or nonsteroidal anti-inflammatory drugs for the prevention of colorectal cancer: U.S. Preventive Services Task Force recommendations.
Topics: Adenoma; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Polyps; Colorectal Neoplas | 2007 |
Routine aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer: U.S. Preventive Services Task Force recommendation statement.
Topics: Adenoma; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Polyps; Colorectal Neoplas | 2007 |
Letter by Cen regarding article, "Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas".
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Celecoxib; Color | 2007 |
Can aspirin prevent colorectal cancer?
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Female; Humans; Mal | 2007 |
Folate and cancer--timing is everything.
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Folic Acid; Humans; | 2007 |
Folic acid and prevention of colorectal adenomas.
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Folic Acid; Humans; | 2007 |
Ornithine decarboxylase G316A genotype is prognostic for colorectal adenoma recurrence and predicts efficacy of aspirin chemoprevention.
Topics: Adenoma; Adult; Aged; Anticarcinogenic Agents; Aspirin; Colorectal Neoplasms; Female; Genes, APC; Ge | 2008 |
Aspirin helps prevent recurring colorectal adenomas--folic acid does not.
Topics: Adenoma; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chemotherapy, Adjuvant; Colo | 2008 |
Dairy products, polymorphisms in the vitamin D receptor gene and colorectal adenoma recurrence.
Topics: Adenoma; Adult; Aged; Animals; Aspirin; Calcium Compounds; Colorectal Neoplasms; Dairy Products; Fem | 2008 |
Effect of aspirin and indomethacin on the formation of benzo(a)pyrene-induced pulmonary adenomas and DNA adducts in A/HeJ mice.
Topics: Adenoma; Animals; Aspirin; Benzo(a)pyrene; Benzopyrenes; Chromatography, High Pressure Liquid; Cyclo | 1983 |
Aspirin prevention update: new data on lung and colon cancers.
Topics: Adenoma; Animals; Aspirin; Colonic Neoplasms; Humans; Lung Neoplasms; Mice | 1995 |
Inhibition of aberrant crypt growth by non-steroidal anti-inflammatory agents and differentiation agents in the rat colon.
Topics: Acetaminophen; Adenoma; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti | 1995 |
Aspirin use and the risk for colorectal cancer and adenoma in male health professionals.
Topics: Adenoma; Adult; Aged; Aspirin; Colonic Polyps; Colorectal Neoplasms; Health Personnel; Humans; Male; | 1994 |
Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats.
Topics: Adenocarcinoma; Adenoma; Animals; Anticarcinogenic Agents; Aspirin; Azoxymethane; Body Weight; Colon | 1993 |
Effect of aspirin and NSAIDs on colorectal adenomas. Protective effect may be spurious.
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Humans | 1993 |
Reduced risk of large-bowel adenomas among aspirin users. The Polyp Prevention Study Group.
Topics: Adenoma; Aged; Aspirin; Colonic Neoplasms; Colonoscopy; Female; Humans; Male; Middle Aged; Surveys a | 1993 |
Differential growth inhibition by the aspirin metabolite salicylate in human colorectal tumor cell lines: enhanced apoptosis in carcinoma and in vitro-transformed adenoma relative to adenoma relative to adenoma cell lines.
Topics: 3T3 Cells; Adenoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Carcinoma; | 1996 |
G1 delay in cells overexpressing prostaglandin endoperoxide synthase-2.
Topics: Adenoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Cell Li | 1996 |
Long-term use of nonsteroidal antiinflammatory drugs and other chemopreventors and risk of subsequent colorectal neoplasia.
Topics: Adenocarcinoma; Adenoma; Aged; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; As | 1996 |
Chemopreventive efficacies of aspirin and sulindac against lung tumorigenesis in A/J mice.
Topics: Adenoma; Animals; Aspirin; Cells, Cultured; Cytochrome P-450 CYP1A2; Enzyme Activation; Female; Huma | 1997 |
A case-control study of dietary intake and other lifestyle risk factors for hyperplastic polyps.
Topics: Adenoma; Aged; Alcohol Drinking; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Body Mass Index; | 1997 |
Aspirin and nonsteroidal anti-inflammatory agents and risk for colorectal adenomas.
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Female; Humans; Mal | 1998 |
Chemoprevention of spontaneous intestinal adenomas in the adenomatous polyposis coli Min mouse model with aspirin.
Topics: Adenoma; Adenomatous Polyposis Coli; Animals; Aspirin; Diet; Dinoprostone; Dose-Response Relationshi | 1998 |
Intestinal tumorigenesis in the Apc1638N mouse treated with aspirin and resistant starch for up to 5 months.
Topics: Adenocarcinoma; Adenoma; Adenomatous Polyposis Coli; Adipose Tissue; alpha-Amylases; Animals; Anti-I | 1999 |
Reduced incidence of colorectal adenoma among long-term users of nonsteroidal antiinflammatory drugs: a pooled analysis of published studies and a new population-based study.
Topics: Adenoma; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Cohort | 2000 |
Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs.
Topics: Adenoma; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cohort Studies; Colorectal N | 2001 |
Inhibition of COX-2 and induction of apoptosis: two determinants of nonsteroidal anti-inflammatory drugs' chemopreventive efficacies in mouse lung tumorigenesis.
Topics: Adenoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Chemoprevention; Cycl | 2000 |
CYP2C9 and UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma risk.
Topics: Adenoma; Adenomatous Polyps; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic | 2001 |